Neural Stem Cells: Exogenous and Endogenous Promising Therapies for Stroke by M. Guerra-Crespo et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
15 
Neural Stem Cells: Exogenous and 
 Endogenous Promising Therapies for Stroke 
M. Guerra-Crespo1,2, A.K. De la Herrán-Arita1, 
 A. Boronat-García1, G. Maya-Espinosa1, 
J.R. García-Montes1, J.H. Fallon3 and R. Drucker-Colín1,2 
1Departamento de Neuropatología Molecular, Instituto de Fisiología Celular  
2 Grupo Células Troncales Adultas, Regeneración Neuronal y Enfermedad de Parkinson 
Universidad Nacional Autónoma de México 
3Department of Psychiatry and Human Behavior, University of California, Irvine 
1,2México 
3USA 
1. Introduction 
In the last three decades, neuroscience has been profoundly involved in stem cell research 
that focuses in attempting to develop mechanisms and strategies for secure therapy for 
different types of brain injury. The limited capacity for cellular regeneration in the highly 
specialized adult brain makes it particularly vulnerable to cellular damage produced by 
injuries, such as stroke, which results in a permanent loss of function. Stroke is a a vascular 
accident characterized by dramatic neuronal loss following a sudden cease of blood flow. 
According to the World Health Organization, 15 million people worldwide suffer a stroke 
event each year. Of those 5 million pass away and another 5 million are permanently 
disabled (World Health Organization, 2007). Chronic stroke can have a devastating impact 
on the patient, family, and caregivers; but it also incurs in high economic costs to society. In 
the United States, stroke is the leading cause of adult disability with an estimated annual 
medical cost of approximately $40 billion.  
High blood pressure contributes to the majority of stroke events, accounting for 12.7 million 
strokes over the world (World Health Organization, 2007). In developed countries, the 
incidence of stroke is declining, largely due to efforts in attempting to lower blood pressure 
and reduce smoking. However, the overall rate of stroke remains high due to the aging of 
the population. 
There are two main types of stroke. One is ischemic stroke, which is caused by a blockage of an 
artery; the other is hemorrhagic stroke, which is the result of a tear in an artery’s wall that 
produces a blood outflow into the brain. Ischemic stroke is the most common type, it accounts 
for about 85 percent of all stroke events (Foulkes et al., 1988). In both cases, prompt treatment 
could mean the difference between life and death. Early treatment can also minimize damage 
to the brain and potential disability. The consequences of stroke on bodily functions and the 
severity of stroke depend on the affected area of the brain and the extent of the damage. 
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1.1 Current treatments for stroke 
In general terms, a stroke event can be divided in acute, sub-acute and chronic phase, by 
taking in consideration the time course of the injury. The therapeutic strategies to each 
relative time point are different and centered to ameliorate different sorts of damage. 
In the acute phase, the use of thrombolytic agents may dissolve the blood clot in order to 
slow down or prevent the cascading process that destroys nerve cells after a few hours of 
ischemic stroke. A currently available and successful intervention to reduce the size of the 
infarct is the employment of recombinant tissue plasminogen activator (t-PA). T-PA allows 
the dissolution of a blood clot occluding a cerebral vessel by converting plasminogen into 
plasmin, an important enzyme present in blood that degrades many blood plasma proteins, 
most notably, fibrin clots. 
Administration of t-PA is approved only within 3 hours of the onset of ischemia, although 
optimal results are observed if given within 90 minutes (Hacke et al., 2004). Unfortunately, 
due to this narrow time window as well as a number of contraindications, t-PA therapy is 
only available to about 5% of stroke patients evaluated in the emergency room. Of these, t-
PA may be expected to yield an approximate of 30% increase in the number of patients 
avoiding long-term neurologic deficits (Ropper & Brown, 2005).  
Surgical interventions have enhanced over time and proved to be effective in some cases; 
however, their success is still below a desired echelon. Although surgical decompression 
after a stroke event has proved to lessen mortality in severe cases, doubling the probability 
to survive in a favorable condition, the odds of surviving in a condition requiring assistance 
from others increases around 10 times (Vahedi et al., 2007). Advances in endovascular 
techniques may improve recanalization sufficiently to improve patient or cell survival, but 
these have yet to be substantiated by randomized clinical trials (Burns et al., 2008). 
Given the narrow window of time in which thrombolytic drugs and surgical procedures are 
effective, current research is focused in developing neuroprotective agents that maintain the 
cellular viability of threatened neuronal tissue (ischemic penumbra) and reduce the 
secondary damage after ischemic stroke. Many drugs currently undergoing investigation 
target the excitatory amino acids, such as glycine and glutamate, released by dying neural 
cells, which are known to lead to downstream changes that destroy nerve cells several hours 
to several days after a stroke. Dejectedly, although a plethora of neuroprotective compounds 
have shown promise in animal models, currently their employment has not shown any 
effectiveness in clinical trials (Dirnagl, 2006).  
This fact implicates that nowadays, not a single treatment has been successful in reversing 
the effects of the chronic stroke. Physical therapy is used to promote functional recovery in 
long-term stroke patients, but recovery is often incomplete. Therefore, reversal of symptoms 
after a chronic stroke is a daunting problem that requires the improvement of the patient’s 
lost function achieved by the replacement of lost neurons and glia in the injured region, as 
well as the establishment of new functional connections. These requirements call for bold 
new treatments that induce new neural cells to differentiate and integrate into the circuitry 
that was damaged by the stroke, the cell replacement therapy. 
Considering the large amount of data acquired over the past four decades, it has been 
confirmed that neural stem cells (NSCs) are present throughout life and that thousands of 
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neurons are born on a daily basis in two specific zones of the brain, the subventricular zone 
(SVZ) and the hippocampus (For extensive review see Zhao et al., 2008).  
NSCs are endowed with a self-renewal capacity and are specified to give rise only to 
nervous tissue-specific cell types, including neurons, glia and oligodendroglia (Reynolds 
and Weiss, 1996). These features together with the recent finding of the NSCs endogenous 
response to certain types of insults, such as stroke, lead to the persistent pursue to replace 
the cellular loss that takes place in the central nervous system (CNS) after injury or 
neurodegenerative diseases. With the advent of neuroregeneration discipline, new insights 
have come to the management of stroke. In general, two broad approaches are currently in 
development for cell replacement therapy in stroke: the recruitment of endogenous neural 
stem cells and exogenous stem cells transplanted into the affected area.  
For a successful therapy, both approaches require to follow a highly regulated process 
known as neurogenesis, defined as the birth or generation of new neurons from NSCs 
(Zhao et al., 2008). Neurogenesis follows a course where important cellular steps such as 
proliferation, migration and differentiation (PMD reponse), as well as cell survival are 
taking place. However, without a doubt, in order to develop a successful cell therapy, 
more understanding about how the neurogenesis process is occurring is of foremost 
relevance.  
To achieve this goal, some important questions emerge: what are the characteristics required 
from the microenvironment that allow the neurogenic process to persist throughout life in 
the adult brain? What are the underlying mechanisms of neurogenesis regulation? And 
what is the cellular and molecular process regulating neurogenesis under pathological 
conditions? 
In this chapter we will describe the current knowledge about the cellular organization and 
the molecular regulation that takes place in the SVZ, mechanisms that could provide the 
basis for the development of cell therapy in stroke and other neurodegenerative diseases. 
Afterward, the chapter will depict the effects of several growth factors with towering 
therapeutic potential for their capacity to induce endogenous cell replacement. Finally, this 
chapter will depict the therapeutic potential of NSCs and other cell types that are suitable 
for transplantation and ergo, for regeneration therapy in human patients afflicted with 
cerebral ischemia. 
2. Cellular and molecular regulation of adult NSCs in the SVZ 
2.1 The SVZ and rostral migratory stream (RMS): A general view 
The study of adult neurogenesis in mammalian CNS began in the 1960’s with the pioneering 
observations made by Joseph Altman, who managed to observe cell proliferation in the 
adult brain with 3H-thymidine, a recognized cell division marker (Altman 1963, 1965, 1969). 
In spite of the controversy, further studies corroborated the existence of brain areas with the 
potential to generate new neurons from NSCs and defined as neurogenic niches. Nowadays, 
it is well accepted that the main neurogenic areas in the adult mammalian brain are the SVZ 
located in the walls of the lateral ventricles and the subgranular layer of the dentate gyrus 
(DG) of the hippocampus (Figure 1).  
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Fig. 1. Stroke and neurogenesis in the subventricular zone . 
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The SVZ contains many cell types, in addition to chemical and physical factors that create a 
special microenvironment, conducive to accurately regulate the self-renewal and 
multipotentiality properties of NSCs (Fuchs et al., 2004). It also regulates the neurogenic 
processes of PMD as well as the less characterized cell integration.  
The cellular composition and cytoarchitecture of the SVZ is remarkable peculiar and 
complex (Figure 1). There are at least five main different cell types integrating the SVZ: 
Astrocytes, also called B cells, divided in B1 (apical B) and B2 (tangential B); transit 
amplifying cells (C cells, the putative precursor); neuroblasts (A cells); tanycytes (D cells) 
and ependymal cells, divided in E1 and E2 (E cells) (Doetsch et al., 1997; Mirzadeh et al., 
2008; Shen et al., 2008). To give rise to new neuron, B cells generate C cells and their 
subsequent division generates A cells that migrate tangentially in clusters via the RMS 
pathway towards the OB (Figure 1) (Doetsch & Alvarez-Buylla, 1996; Lois et al., 1996). In the 
OB, neuroblasts migrate radially to the granular and glomerular layers, where they 
differentiate as local interneurons and integrate into functional circuits (Belluzzi et al., 2003; 
Carleton et al., 2003; Kosaka et al., 1995; Whitman et al., 2007). Although uncertain, the 
functional relevance of the cell replacement that occurs in the OB throughout the lifespan of 
rodents is attributed to the olfactory adjustment to odor changes in the environment.  
Without a doubt, the features shared by the many cellular types of the SVZ contributed to 
the debate about the true identity of NSCs (for review, Chojnacki et al., 2009). Mitotic cells 
(astrocytes or B cells) have been generally considered to be the true NSCs, owing to their 
self-renew capacity and their ability to indefinitely produce neuronal and glial progeny 
(García-Verdugo et al., 1998; Doetsch et al., 1999). Nevertheless, in vivo observations suggest 
that ependymal cells function as NSCs (Johansson et al., 1999). Nowadays, astrocytes are the 
current accepted NSCs in the adult SVZ. Nonetheless, it is well accepted that the combined 
stimuli of injury and a growth factor (e.g. transforming growth factor alpha,TGFα) induces a 
PMD response by NSCs in the ependymal layer and in the SVZ (Gleason et al., 2008; Guerra 
et al., 2009). 
More recently, the presence of NSCs has been determined in the RMS (Gritti et al., 2002), 
which was considered solely as a migratory pathway for neuroblasts that were migrating 
rostrally from the SVZ to their final destination, the OB (Lledo et al., 2008). This cellular 
movement within the RMS is called “chain migration”, a term established by Lois and 
coworkers in 1996; they showed that neuroblasts migrated in clusters without axonal 
guidance or radial glia regulation and instead, used a network of astrocytes that form “glial 
tubes” (Lois et al., 1996). This unique type of migration is thought to enable cells to draw on 
neighboring cells as their scaffold for migration (Murase & Horwitz, 2002).  
The close proximity to the striatum, shared by the SVZ and the RMS raised interest as a 
cellular replacement option for focal stroke occurring at the basal ganglia. Several molecules 
have been implicated in the highly regulated neurogenesis processes taking place in both 
areas. Some of them play multiple essential roles by regulating different levels of the PMD 
response. For the development of a thriving cell therapy, it is essential to control the 
processes of proliferation and migration, by means of increasing the number of proliferating 
cells and redirecting them to the injured area. Therefore, the mechanisms that will allow us 
to control neuronal fate are of great interest in the neurorepair field and represent a 
promising subject for the development of a factual clinical treatment.  
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In the following fraction, we describe the main molecules and cellular events that have been 
involved in the NSCs differentiation route. Table 1 summarizes the main findings. 
2.2 Regulation of the NSCs development in the OB pathway 
The tangential homotypic traverse of the cells that depart from the SVZ through the RMS 
is finely controlled by several molecules at different levels. Growth factors are the main 
mitogenic signals received by NSCs that trigger cell division. A subsequent generation of 
neuroblasts takes place after such signals; these neuroblasts are confined within the RMS 
via the combined effect of diffusible chemoattractants and chemorepellents that are 
flowing at a concentration gradient from the SVZ to the RMS. Noteworthy, the precise 
migration route is determined by cell-cell interaction mechanisms to ascertain their 
oriented organization into a continuous alignment. This migration configuration requires 
individual morphology arrangements in the wanderer neuroblasts, in order to make them 
suitable for migration. 
2.2.1 Growth factors: Regulating multiple effects 
Growth factors and neurotrophins have been implicated in the regulation of neurogenesis at 
early and postnatal development by controlling proliferation, migration and differentiation. 
Here, we describe some of these factors, including epidermal growth factor (EGF), fibroblast 
growth factor-2 (FGF-2), TGF, brain derived neurotrophic factor (BDNF) and vascular 
endothelial growth factor (VEGF) for their critical role in these processes.  
2.2.1.1 EGF, TGF and FGF-2: Mitogenic signals 
EGF and TGF, two members of the EGF family, were the first growth factors to be 
associated to regulate SVZ proliferation through its binding to EGF receptor (EGFR). This 
tyrosine kynase receptor has been immunodetected in C cells (Doetsch et al., 2002) and in 
astrocytes of the SVZ (Höglinger et al., 2004). In vitro, studies have demonstrated that NSCs 
derived from the SVZ proliferate in the presence of EGF or FGF-2, as free-floating 
neuroespheres that have the potential to differentiate into neurons and glia under 
appropriate conditions (Doetsch et al., 1999; Gritti et al., 1999; Reynolds & Weiss, 1992). In 
vivo, intraventricular infusion of EGF and TFG resulted in an increase of NSCs 
proliferation in the SVZ (Craig et al., 1996; Khun et al., 1997; Morshead et al., 2003). 
Grippingly, only TGF-knockout mice presented a significant reduction in proliferation and 
neuroblast migration in the SVZ and RMS (Tropepe et al., 1997), pointing out its direct role 
in these two cellular processes.  
Alternatively, FGF is a large family that is widely expressed in the central nervous system. 
Twenty-two members of the FGF family have been identified in humans (Itoh & Orniz, 
2011) and have been related to several neuronal processes, for instance, development, adult 
neurogenesis and repair mechanisms (Reuss & von Bohlen, 2003). To accomplish its 
mentioned functions, FGF binds with different affinity to each one of the FGF receptor 
(FGFR) family, integrated by four different members (FGFR 1 to 4) (Ornitz et al., 1996, 
Johnson & Williams, 1993). 
From all the integrants of the FGF family, FGF-2 is the one commonly related to regulate adult 
neurogenesis. FGF-2 and its receptor, FGFR-1, have been described in the SVZ (Mudó et al., 
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2007). In vitro, FGF-2 stimulates the proliferation of NSCs located in the SVZ and that these 
progenitors expressing nestin (neural progenitor marker) are able to differentiate into several 
brain cell types including neurons (Gritti el al., 1996, 1999). In vivo studies demonstrated that a 
subcutaneous injection of FGF-2 increases mitotic activity in the adult SVZ (Wagner et al., 1999) 
and restores the proliferative rates in aging rats (Fluxe et al., 2008; Jin et al., 2003). Nevertheless, 
the expression levels of FGF-2 and FGFR-1 in the SVZ do not change during aging, suggesting 
that although FGF-2/FGFR-1 interaction is involved in cell proliferation, it does not regulate 
the age-dependent declining of NSCs proliferation (Frinchi et al., 2010).  
2.2.1.2 BDNF: A multitask molecule 
A neurotrophin recognized to undertake multiple roles in SVZ neurogenesis is BDNF. 
BDNF and its receptors of high and low affinity, TrkB and p75NTR, respectively, are 
expressed all over the SVZ-RMS in a mutually exclusive pattern; with higher expression of 
BDNF and TrkB in the RMS when compared to the SVZ (Bath et al., 2008; Chiaramello et al., 
2007; Galvão et al., 2008; Gascon et al., 2007; Giuliani et al., 2004; Maisonpierre et al., 1990; 
Snapyan et al., 2009; Young et al., 2007). In the adult RMS, BDNF mRNA expression was 
identified in endothelial cells of blood vessels, and absent in astrocytes as well as 
neuroblasts (Snapyan et al. 2009), whereas TrkB was found predominantly in astrocytes 
(Snapyan et al. 2009). Conversely, active TrkB (phosphorylated form) as well as the low 
affinity receptor p75NTR have been observed in migrating neuroblasts (Bath et al., 2008, 
Galvão et al., 2008; Snapyan et al., 2009). P75NTR is also present in a small subset of GFAP-
immunopositive cells and transit amplifying cells (C-cells) in the RMS (Bath et al., 2008, 
Galvão et al., 2008; Snapyan et al., 2009).  The BDNF-TrkB-p75 interaction is correlated to 
multiple cellular processes in the SVZ-RMS, in particular, those regarding survival, 
proliferation, migration and cell differentiation. 
Luskin and Goldman’s groups, who were working independently in a parallel fashion, were 
the firsts studying the effect of BDNF on adult neurogenesis. They both demonstrated that 
infusion or overexpression of BDNF into the lateral ventricles increased cell proliferation in 
the SVZ and migration through the default migratory pathway towards the OB (Benraiss et 
al., 2001; Pencea et al., 2001; Zigova et al., 1998). Of equal relevance, was their discovery that 
a higher number of newborn neurons occur in the OB, highlighting its role in differentiation. 
Simultaneously, new heterotopic spiny neurons were found in the striatum; this finding 
raises the possibility to redirect the migration of neuroblasts after BDNF infusion, an 
astonishing breakthrough for endogenous replacement therapy (Benraiss et al., 2001; Pencea 
et al., 2001). 
More recently, an additional function has been attributed to BDNF, the chemoattraction; 
defined as the movement of cells towards a chemical concentration gradient. Chiaramello et 
al., tested the hypothesis that the lower expression pattern of BDNF in the RMS and a higher 
expression pattern in the OB is consistent with the chemoattraction property. 
In explants cell cultures, the addition of this neurotrophin resulted essential for survival in 
addition to, a dose-dependent increase of migrating newly dividing cells. Interestingly, 
BDNF-induced motility on SVZ neuroblast explants was suppressed by blocking TrkB 
receptor autophosphorylation and by blocking BDNF action with neutralizing antibodies 
(Chiaramello et al., 2007). Together, these results prove that BDNF has a chemoattractive 
function through an autocrine and/or paracrine signaling.  
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Despite the conclusive data concerning BDNF, the mechanisms responsible for maintaining 
the cells in proper formation while navigating towards the OB core still are unclear. New 
relevant information comes out from an interesting study from Snapyan and coworkers. 
They identified BDNF as a molecular signal released from endothelial cells of blood vessels 
(not from astrocytes or neuroblasts) in the SVZ-RMS, and demonstrated that it promotes 
neuronal migration via p57NTR activation on neuroblasts (Snapyan et al., 2009). They 
proposed a vasculature-guided migration model in which migrating neuroblasts in the RMS 
are retained and migrate along this pathway, secondary to the presence of blood vessels that 
are oriented in a parallel fashion to the RMS (Snapyan et al., 2009). This newly proposed 
model however, does not exclude the previously stated chemoatraction model, since the 
possibility that both mechanisms are operating is plausible (Snapyan et al., 2009). 
2.2.1.3 VEGF: Regulator of proliferation and a probable chemoattractive molecule in the 
SVZ 
Another growth factor regulating cellular proliferation in the SVZ is VEGF, a glycoprotein 
known to be involved in angiogenesis and vasculogenesis. Intraventricular infusion of 
VEGF leads to an increase in cell proliferation of the SVZ (Jin et al., 2002; Sun et al., 2006). 
This finding has been confirmed by inducing the overexpression of VEGF in an ischemic 
model, where an increase in SVZ proliferation and migration of new cells into the ischemic 
injury was observed (Wang et al., 2007a, 2007b).  
The VEGF family ranges from VEGF-A to VEGF-D factors, which have an affinity to several 
tyrosine kinase receptors: VEGF receptor (VEGFR) 1 (Flt1), VEGFR2 (KDR/Flk1), VEGFR3 
(Flt4) and neuropilin receptors (NP1/2) (Matsumoto & Claesson-Welsh, 2001). One of these 
receptors, VGFR2, has been demonstrated to mediate a chemotactic activity for VEGF in cell 
cultures (Zhang et al., 2003). Its role as a chemoattractive guidance molecule for migrating 
neural progenitors arising from the SVZ only takes place when these cells are maintained 
under FGF-2 administration. These in vitro essays show that FGF-2 stimulates neural 
progenitors to express VGFR2, which confers them the capacity to respond to VEGF (Zhang 
et al., 2003).  
The chemoattractant function of VEGF in adult brain is still not clear. In vivo, 
intraventricular VEGF administration revealed that VEGFR2/Flk-1 receptors predominate 
in neurogenic niches such as the SVZ and co-localize with migrating neuroblasts as well as 
astroglial, endothelial and neuronal cells (Jin et al., 2002; Schänzer et al., 2004). VEGF 
expression is observed in astrocytes, being higher in astrocytes of the SVZ and RMS than in 
astrocytes from non-permissive regions (Balenci et al., 2007). This expression represents an 
endogenous source of VEGF that can be related to neurogenesis and might have a direct 
effect on the migration of neural progenitors within neurogenic regions (Balenci et al., 2007).  
2.2.2 Chain migration: Molecules implicated 
Neuroblast chain formation requires a myriad of specific and regulated interactions to 
constrain the migrating cells into a precisely organized shape of the RMS. Here, we are 
describing the main molecules orchestrating the cellular processes involved in chain 
formation.  
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2.2.2.1 Ephrin family: Driving proliferation and proper cell positioning in migrating 
chains 
Ephrins are transmembrane-associated proteins that exert their actions through its binding 
to Ephrin (Eph) receptors; the largest family of tyrosine kynase receptors. Ligands and 
receptors are divided in two subclasses (A and B), based on their binding properties and 
structural homologies (Mosch et al., 2010). In general, ephrin-A ligands (ephrin-A1 to A6) 
bind preferentially to EphA receptor (EphA1 to A9), whereas ephrin-B (ephrin-B1 to B3) 
ligands bind to EphB receptor (EphB1 to B6). The interaction triggers a bidirectional cascade 
signal, where ephrins mediate a “reverse” signal and receptors mediate a “forward” signal 
(Cowan & Henkemeyer, 2002). 
Ephrins-Eph interaction during development has been implicated in multiple roles, 
including axonal growth and cell guidance (For review see Wilkinson, 2001). In the adult 
brain, this interaction has also been related to several roles during neurogenesis (Conover et 
al., 2000; Holmberg et al., 2005; Theus et al., 2010).  
The SVZ and RMS express Eph-B1-3 and EphA4 receptors (Conover et al., 2000; Theus et al., 
2010). In the RMS, EphB2 receptor seems to be surrounding chains of migrating neuroblasts, 
whereas cells expressing EphB2 in the SVZ are yet still to be determined (astrocytes, 
neuroblasts or ependymal cells) (Conover et al., 2000). On the other hand, ephrin-B ligands 
are expressed in astrocytes that envelop chains of migrating neuroblast along the RMS 
pathway. This ephrin/Eph complementary expression pattern seems to regulate the classic 
ephrin contact-mediated repulsive response to give a position to the cells in specific sites. 
Interestingly, blocking Ephrin-B/EphB interactions originates an increase in astrocyte 
proliferation in the SVZ and promotes a disorganization of the chain network (Conover et 
al., 2000). Therefore, ephrin-B/EphB interaction is a negative regulator of cell proliferation 
and controls spatial organization in the SVZ. Additionally, this result suggests that 
inhibition of cell proliferation is required to maintain the germinative niches homeostasis.  
Recently, Theus and collaborators revealed the anti-proliferative effect of EphB3, another 
EphB receptor in the SVZ. EphB3 is expressed in neuronal stem progenitor cells and in 
neuroblasts. In the traumatic brain injury (TBI) model, where an increase in neurogenesis in 
the SVZ is induced, Theus’s group observed a significant reduction of EphB3 expression, 
coincidently with enhanced NSCs precursors survival and proliferation post-injury. These 
findings were corroborated in both ephrin-B3 and EphB3 knockout mice. The two models 
showed a significant augmentation in SVZ proliferation. Interestingly, in ephrinB3-/- mice, 
cell division can be reverted by infusion of a soluble form of ephrinB3 (ephrinB3-Fc) in the 
lateral ventricle. Furthermore, its infusion also prevents TBI-induced neural stem progenitor 
cell proliferation (Theus et al., 2010).  
Studies made in ephrin subclass A receptors gave similar results to the ones observed on 
ephrin-B. The use of ephrin-A2 and ephA7 knockout mice showed that this ligand-receptor 
interaction is a key inhibitor of cell proliferation in adult brains (Holmberg et al., 2005). 
Ephrin-A2-/- and EphA7-/- mice show an increase in SVZ proliferation concomitant to an 
increase in the number of new cells in the OB; suggesting that these cells migrate in a 
regular fashion to the OB. In this study, it was observed that Ephrin-A2 is expressed in 
neural progenitor cells and neuroblasts of the lateral ventricles, whereas EphA7 receptor 
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was expressed in ependymal cells and astrocytes of the SVZ. Interestingly, once again it 
seems that they are localized in a mutually exclusive manner, proper to promote ligand-
receptor interactions (Holmberg et al., 2005). 
Altogether, these findings indicate that ephrin signaling is involved in the regulation of at 
least two processes of adult neurogenesis, the proliferation and neuroblast guidance into 
migrating chains, although, the mechanisms controlling these events still have to be 
determined.  
2.2.2.2 ErbB receptors and neuregulins: Chemoattractive implications in proliferation and 
migration 
The ErbB family, also called EGFR family, is integrated by four related tyrosine kinase 
receptors (ErbB1-ErbB4); one of them involved in cell migration signaling. Anton and 
coworkers determined that ErbB4 is expressed in neuronal precursor cells (type A cells) 
residing in the SVZ and the RMS. Additionally, in a small subset of type B cells and type C 
cells (Anton et al., 2004). Ghashghaei and collaborators detected the presence of ErbB4 in a 
subgroup of CD24+ ependymal cells (Ghashghaei et al., 2006). 
Experiments in mice lacking ErbB4 receptor, determined its role in the organization of the 
SVZ-RMS pathway (Anton et al., 2004). ErbB4-null mice had a disorganized structure of the 
SVZ, whereas the neuronal precursors, typically organized in clusters of chains along the 
SVZ and RMS, were instead forming fragmented chains that migrated as individual cells 
with an altered orientation. Moreover, impaired placement of interneurons in the OB was 
observed. In vitro, explants from these mutant mice were also unable to form compact 
neuronal chains, suggesting that loss of ErbB4 disrupts the characteristic “glial” tubular 
organization in the RMS (Anton et al., 2004).  
In the SVZ, ErbB4 receptors can be activated by neuroregulins (NRGs), proteins belonging 
to the EGF family and directly involved in the migration process as chemoattractants (Anton 
et al., 2004). NRGs are a family of four signaling proteins that mediate cell-cell interactions in 
different organs, including the brain. They have been related to the activation of 
intracellular signaling pathways that lead to specific cellular responses, including 
stimulation or inhibition of proliferation, apoptosis, migration, differentiation and adhesion 
(Yarden et al., 2001).  
Two NRG types, NRG1 and NRG2, are controlling adult neurogenesis, in particular, cell 
proliferation and migration. NRG1 type III isoform is highly expressed in the RMS and the 
OB in the early postnatal development period (Anton et al., 2004). In vitro, NRG1 type III has 
been characterized as the preferred chemoattractive protein (compared to NRG1 type I), 
aiding the migration of neuronal precursor cells from the SVZ (Anton et al., 2004).  
NRG2 is expressed by immature neuroblasts and in a subset of astrocytes that are lining the 
ventricles of the SVZ (Ghashghaei et al., 2006). Ghashghaei and collaborators demonstrated 
that NRG1 and NRG2 have different functions in the same niche. Intraventricular infusion 
of NRG1 induces the aggregation of proliferating precursors into clusters in the SVZ. This 
aggregation is fundamental for their proper migration, probably by a chemoattractive 
property. On the other hand, intraventricular infusion of NRG2 promotes astrocyte 
proliferation and a subsequent increase of neuroblast and GABAergic interneurons in the 
olfactory bulb (Ghashghaei et al., 2006). 
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2.2.2.3 integrins: Receptors regulating chain formation and migration through laminin 
binding 
Integrins are heterodimeric cell surface glycoproteins that regulate proliferation and cell 
adhesion. Their mechanism of action is mediated through the binding to ECM proteins 
(fibronectin, laminin), other proteins such as ADAMs (a desintegrin and metalloprotease) 
and Ig-superfamily cell surface counter-receptors (such as VCAM-1). Two different subunits 
have been identified,  and , which assemble at least into 24 distinct types of 
integrins (Hynes, 2002). 
Integrins play an important role directing the migration of neuronal precursors 
demonstrated in both in vivo and in vitro experiments. At least 11 integrin subunits have 
been identified in the SVZ-RMS pathway (1, 2, 3, 6, 7, v, 1, 3, 5, 6 and 8) with 
modifications in the temporal expression pattern during development (Belvindrah et al., 
2007; Murase & Horwitz, 2002). The expression of 1, 6, and 7 integrin subunits in 
neuroblast of the RMS seems to be higher than the one observed in the SVZ (Belvindrah et 
al., 2007) and grippingly, all of them are able to heterodimerize with a 1 subunit (Hynes, 
2002). A model for NSCs-vascular niche adhesion in the SVZ proposes integrins as a 
receptor for laminin, a protein deposited between neuroblasts and mainly expressed by 
endothelial cells that surround the SVZ. Laminin is a chemoattractant molecule for SVZ-
RMS neuronal precursors that has been proposed to promote cell-cell interactions for chain 
formation via binding to1-integrin (Belvindrah et al., 2007). As a counterpart, 5 integrin is 
dispensable for chain migration. 
Another integrin, 61, is expressed in chain migrating cells along the rodent SVZ-OB 
pathway, mainly in cell-cell junctions (Belvindrah et al., 2007; Emsley & Hagg, 2003; 
Jacques et al., 1998). Laminin is the only known ligand for 61 integrin. It has been 
observed that laminin is recruited to the cell surface of migrating neuroblasts, where it 
induces chain formation in SVZ explants and the aggregation of neuronal precursors in 
vivo. In addition, it also induces chain migration in vitro and in vivo (Belvindrah et al., 
2007; Emsley & Hagg, 2003). Worthy of notice, laminin infusion, in regions where 
precursor cells are not normally seen, redirects neural precursors toward these locations, 
as it has been observed in the neostriatum (Emsley& Hagg, 2003). The evidence, strongly 
supports the idea that laminin-61 interaction is involved in the directional guidance of 
neuronal precursors, and promotes the formation of cell chains in the adult RMS, as well 
as maintaining the integrity of glial tubes in the RMS (Belvindrah et al., 2007; Emsley & 
Hagg, 2003).  
2.2.2.4 Poly-sialated neural-cell adhesion (PSA-NCAM) molecule: Forming the chain 
migration process and controlling differentiation  
NCAM is a cell surface glycoprotein, member of the immunoglobulin superfamily that 
mediates cell-cell homotypic interactions, while PSA is a polymer of neuroaminic acid 
residues added to the NCAM molecule that is highly expressed during development and 
persists in the adult nervous system. Interestingly, in the adult brain, its expression is 
particularly confined to neurogenic niches (Seki & Arai, 1993). Specifically, neuroblasts 
conforming the chain migration in the RMS express PSA-NCAM (Rousselot et al., 1995). 
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In explants cultures, it has been observed, the absence of PSA produced by 
endoneuraminidase-N (endoN) treatment incites the dispersion of migrating chains, 
although neuroblasts are still able to migrate as single cells (Hu, 2000). Furthermore, in vivo 
essays demonstrate that these cells do not easily disperse, probably because the tubular glial 
structures that are ensheating the neuroblasts are confining the migrating cells (Hu, 2000). 
This clearly indicated that lack of PSA causes a decrease in cell-cell interactions in neural 
progenitor chains. Therefore, PSA is an important element for neuroblast chain formation 
(Hu, 2000).  
Other studies have demonstrated that PSA is additionally controlling neuroblast 
differentiation (Battista et al., 2010; Petridis et al., 2004). Removal of PSA moieties secondary 
to endoN administration inhibits cell contact dependent differentiation in vivo. Furthermore, 
it promotes a minimal and ectopic dopaminergic differentiation of neural progenitors in the 
SVZ (Petridis et al., 2004). PSA elimination can also result in a dispersal of progenitor cells 
from the SVZ to the surrounding regions such as cortex and striatum, where neuroblasts 
differentiate into a calretinin and GABAergic phenotypes (Battista et al., 2010). 
The effects of NCAM mutations are quite different compared to the ones observed after PSA 
depletion. NCAM mutations produce a dramatic size reduction of the OB (~30%), while 
disruption of PSA increases this effect (Cremer et al., 1994). PSA-NCAM deficient mice have 
an altered RMS, where the normal borders are exceeded as a result of an altered 
accumulation of migrating cells (Chazal et al., 2000).  
Altogether, it seems that PSA-NCAM mutations lead neural precursors to fail in the 
tangential migration to the OB. On the other hand, the ability to migrate radially into the 
same structure remains unaltered under PSA removal. This was demonstrated after 
transplanting SVZ cells in the OB of normal and PSA depleted mice OBs (by endoN), in both 
cases, no differences in radial migration distance or cell morphology were detected, which 
indicate that PSA does not regulate radial migration (Hu, 1996).  
2.2.2.5 Doublecortin (DCX): Cytoskeletal dynamics for cell translocation 
DCX is a neuron-specific phosphoprotein associated with microtubules that is localized in 
cell bodies and leading processes. It is involved in the regulation of cytoskeletal dynamics. It 
is expressed in neuroblasts (type A cells) and immature neurons wherein induces 
polymerization, in addition to promote the stabilization of microtubules that contribute to 
cell locomotion (Francis et al., 1999, Gleeson et al., 1999). 
DCX expression is downregulated in postmigratory neurons in the OB. Its co-distribution 
with PSA-NCAM characterizes early committed neurons within the RMS; therefore, DCX is 
selectively expressed in migratory cell populations within the SVZ, RMS and proximal OB 
(Moores et al., 2004; Ocbina et al., 2006).  
This factor promotes and maintains a bipolar cell morphology, which allows nuclear 
translocation and therefore cellular migration. DCX deletion results in alterations of the 
RMS, instigating a thickening of the RMS by the double of its size; it also results in a 
multipolar neuroblast morphology that correlates to a pause in migration. Furthermore, the 
migratory cells suffer from an unpaired nuclear translocation towards the centrosome and 
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undergo some defects in the length of leading processes, which suggests a failure in neurite 
stabilization (Koizumi et al., 2006). 
2.2.2.6 A Desintegrin And Metalloproteinase (ADAM) protein: Propelling migration  
ADAM proteins are transmembrane proteins formed by metalloprotease and desintegrin 
domains. These molecules appear to be related to neuroblast migration, given the fact that 
other proteins involved in this process require cleavage-dependent activation promoted by 
ADAMs. The possible mechanism of regulation might be the high capacity of ADAMs to 
bind to integrins, which, as previously mentioned, are fundamental to this process (Yang et 
al., 2006). ADAMs are widely expressed in the CNS and approximately 17 different ADAMs 
have been detected in the CNS, however, so far, only ADAM2 and ADAM21 are directly 
related to SVZ-RMS cell dynamics (Murase et al., 2008; Yang et al., 2005). 
ADAM2 is a protein expressed in the RMS neuroblasts. Lack of ADAM2 results in defects in 
migration and morphological alterations of the RMS, which is caudally thicker and rostrally 
thinner, as seen in ADAM2-null mice. ADAM2 probably regulates migration by promoting 
polarized cell morphology that enables migration, since ADAM2-knockout mice present 
short leading cell processes and a slow cell migration rate compared with neuroblasts in 
wild type mice (Murase et al., 2008).  
ADAM21 is a protein expressed in ependymal and SVZ cells. The cell processes extending 
from the SVZ that express ADAM21 are surrounded by glial cells and project to blood 
vessels that course along the RMS. They are associated with integrin ┙6┚1 in neuroblasts 
and its location among neural progenitors and neuroblasts suggest that ADAM21 is 
involved in both cell proliferation and migration (Yang et al., 2005). 
2.2.2.7 Chondroitin Sulphate Proteoglycans (CSPGs): Confinement of neuroblast 
migration 
Chondroitin sulfate is a sulfated glycosaminoglycan (GAG), composed of repeated 
disaccharide units of glucoronic acid (GlcA) and N-acetylgalactosamine (GalNAc). It is 
commonly attached to proteins as part of a proteoglycan and is a major component of the 
ECM that interacts with other proteins due to its negative charges (Viapiano & Matthews, 
2006).  
The adult brain is composed of a type of glia hallmarked by the expression of chondroitin 
sulfate proteoglycan NG2; which are called NG2 cells. These glial cells are widely 
distributed in the CNS, are present in multiple branched processes and have the capacity to 
differentiate into oligodendrocytes (Dawson et al., 2003).  
NG2 cells are aligned along the border of the SVZ and are more abundant as they are 
further distal to the RMS, being higher in the OB. This spatial pattern suggests a correlation 
between neuroblast maturity and the presence of NG2 cells. Furthermore, in the glomerular 
cell layer of the OB, these cells are in direct contact to cells expressing immature and mature 
neuronal markers (DCX, PSA-NCAM and the neuronal nuclear antigen, NeuN). The spatial 
organization of NG2 in SVZ-RMS raises the possibility that these cells confine the migration 
of neuroblasts within the RMS and prevents its dispersion (Komitova et al., 2009) However, 
to make this assumption further research is required.  
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2.2.2.8 Slit and Robo proteins, chemorepulsive interactions for appropriate migration 
Slit and Roundabout (Robo), ligand and receptor respectively, are evolutionarily conserved 
proteins in Drosophila and vertebrates. In mammals, Slit1-3 and Robo1-3 have been 
identified and implicated in axonal repulsion and cell guidance (Brose and Tessier-Lavigne 
2000). Slit is a secreted protein that binds directly to Robo and functions as a chemorepellent 
for OB axons (Li et al., 1999). 
Slit and Robo function on the migratory pathway just started to be unraveled through in 
vitro experiments. Brain explants show that Slit 1 and Slit2 are expressed in the septum, 
where it repels progenitor cells rising from the SVZ and maintained along the RMS (Wu et 
al., 1999). Moreover, Slit2 is expressed in the choroid plexus where it repels neural 
progenitors (Hu, 1999). Given the fact that Robo2 and Robo3 receptor expression has been 
determined in the SVZ and RMS (Marillat et al., 2002), it is presumable that a Slit-Robo 
interaction is occurring in the migratory stream.  
Slit1 deficient mice contributed to clarify the role of Slit1 in SVZ migration. Neuroblasts 
raised from the SVZ of knockout Slit1 mice migrate caudally to the corpus callosum, 
rather than to the RMS, which supports the idea that Slit1 plays an important role in 
directing migration. Moreover, Slit1 is also expressed in type A and type C cells within 
the SVZ and RMS, indicating that Slit presence is not limited to chemorepulsion activity, 
but possibly in parallel way, act as a individual cell migration inhibitor and might 
maintain chain migration integrity because Slit-mutant neurospheres migrate farther and 
in a disperse manner (Nguyen-Ba-Charvet et al., 2004). Therefore, the evidence suggests 
that Slit1 and Slit2 are involved at least, in the beginning of the cell migration pathway 
from the SVZ towards the OB, orchestrating migration through a concentration gradient 
(Wu et al., 1999).  
2.2.2.9 Semaphorin-Neuropilin complex: Does it regulate SVZ-RMS migration? 
Semaphorins are axonal guidance molecules with attractant or repellent activity that 
participate in early development, angiogenesis and cell migration (Tamagone & Comoglio, 
2000). In vertebrates, semaphorins are divided in two groups; class 3 for secreted 
semaphorins and classes 4 to 7, which include transmembrane semaphorins (Raper, 2000). 
There is one receptor family manly involved in the regulation of semaphorin responses in 
the CNS: The neuropilins, NP1 and NP2 (De Wit & Verhaagen, 2003; Raper, 2000). 
Neuropilins are preserved throughout the entire adulthood (Giger et al., 1998) and it is well 
known that these receptors maintain and stabilize neuronal connections and prevent axonal 
sprouting (Giger et al., 2000; Wit & Verhaagen 2003).  
Semaphorin 3A and its homodimer receptor NP1 are present along the entire RMS in the 
adult brain; they appear to be related to the regulation of neuroblast migration. NP1 is 
located in endothelial cells and binds to VEGF, an important angiogenic factor (Soker et al., 
1998). Therefore, it has been suggested that semaphorin 3A modulates angiogenesis. This 
might support the notion that the guidance of migrant neuroblasts chains could be 
regulated by semaphorin 3A through the indirect action of remodeling blood vessels 
(Melendez-Herrera et al., 2008). 
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Complex/Molecule 
Migration 
/Participate in 
proliferation(*) 
Cell type expression 
Reference 
Receptors Ligands 
Growth 
Factors 
EGF-EGFR 
Negative effect on 
neuroblast migration 
(*+) 
EGFR:C cells, 
neuroblasts, and 
astrocytes 
Neuronal precursor 
cells 
Craig et al., 
1996; Doetsch 
et al., 1999; 
Doetsch et al., 
2002; Gritti et 
al., 1999; Kim 
et al. 2009; 
Morshead et 
al., 2003; 
Reynolds & 
Weiss, 1992; 
Tropepe et 
al., 1997 
EGF-TGF Neuroblast migration 
(*+) 
TGFAstrocytes 
BDNF-TrkB
Autophosphorylation 
induces motility on 
SVZ neuroblasts (*+) 
TrkB:migrating 
neuroblasts 
TrkB-T1: astrocytes 
and ependymal 
cells 
BDNF:Endothelial 
cells 
 
Maisonpierre 
et al., 1990; 
Giuliani et al., 
2004; 
Chiaramello 
et al., 2007; 
Gascon et al., 
2007; Young 
et al., 2007; 
Galvão et al., 
2008; 
Snapyan et 
al., 2009 
BDNF-
P75NTR 
Promotes neuroblast 
migration 
P75NTR: 
Neuroblasts, 
astrocytes and C-
cells 
FGF-2 
Cell guidance with 
VEGF interaction (*+)
FGFR: Neural 
precursors 
(Nestin+) 
FGF-2:Glial cells 
Mudó et al., 
2007; Frinchi 
et al., 2010 
VEGFR- 
VEGF 
Neuroblasts guidance 
(*+) 
VEGFR: 
Neuroblasts 
VEGF:Astrocytes, 
endothelial cells 
Jin et al., 
2002; Zhang 
et al., 2003; 
Schänzer et 
al., 2004;  
Schmidt el al., 
2009 
Tyrosine kinase 
receptors 
Ephrins 
Chain organization 
(*-) 
EphB3:C cells and 
neuroblasts 
EphA7:Ependymal 
cells and astrocytes
Ephrin B:Astrocytes 
Ephrin 
A2:Neuroblasts 
Conover et 
al., 2000; 
Holmberg et 
al., 2005 
Erb 
ErbB4:Chain 
organization 
NRG1:Neuroblast 
aggregation 
NRG2:SVZ-cell 
organization (*+) 
ErbB4:Neuroblasts, 
C cells, ependymal 
cells 
NRG1:Neuroblasts 
NRG2:Neuroblasts 
and astrocytes 
Anton et al., 
2004; 
Ghashghaei 
et al., 2006 
Integrins Integrins 
Neuroblast 
aggregation and 
chain formation (*+) 
┙6┚1-integrin: 
Neuroblasts and 
NSCs 
Laminin:Recruited to 
the cell surface of 
neuroblasts 
Highly abundant 
around blood vessels 
in endothelial cells 
Jacques et al., 
1998; Emsley 
& Hagg, 
2003; 
Belvindrah et 
al., 2007; 
Shen et al., 
2008 
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Complex/Molecule 
Migration 
/Participate in 
proliferation(*) 
Cell type expression 
Reference 
Receptors Ligands 
Immunoglobulin 
superfamily 
PSA-NCAM
Chain formation.  
Cell adhesion for 
translocation 
- 
Neuroblasts 
and non-migrating 
glial progenitors 
Seki and Arai 
1993; Hu et 
al., 1996; 
Chazal et al., 
2000; Petridis 
et al., 2004 
Microtubule-
associated 
proteins 
DCX 
Stabilization of 
microtubules. Bipolar 
morphology for 
nuclear translocation
- Neuroblasts 
Francis et al., 
1999; Gleeson 
et al., 1999; 
Moores et al., 
2004; Ocbina 
et al., 2006 
Extracelular 
matrix 
molecules 
ADAMs 
Chain formation. 
Maintains cell 
morphology 
Integrins 
ADAM2:Neuroblasts 
(RMS) 
ADAM21:Ependymal 
and SVZ cells 
Komitova et 
al., 2009; 
Murase et al., 
2008 
Viapiano et 
al., 2006; 
Yang et al., 
2006 
CSPGs Neuroblast migration Integrins NG2 glial cells 
Viapiano et 
al., 2006; 
Komitova et 
al., 2009 
Tenascin-R 
Radial migration in 
OB 
Not determined 
Granular layer of the 
OB 
Saghatelyan 
et al., 2004 
Slit-Robo Slit-Robo Chemorepulsion 
Robo1:OB 
Robo2 and Robo3: 
SVZ-RMS 
neuroblasts 
Slit1 and 
Slit2:Septum 
Slit1:Type A and C 
cells 
Li et al., 1999; 
Wu et al., 
1999; Marillat 
et al., 2002; 
Nguyen-Ba-
Charvet et al., 
2004 
Semaphorin-NP 
Semaphorin-
NP 
Suggested that 
modulates neuroblast 
migration 
NP1:Endotelial 
cells (RMS) 
Semaphorin 3A: 
Endothelial cells 
(RMS) 
Tamagone 
 & 
 Comoglio 
2000; 
Meléndez      
-Herrera et 
al., 2008 
Reelin/ApoER2-
VLDLR 
Reelin/ 
ApoER2-
VLDLR 
Radial migration in 
the OB by cell 
detachment 
ApoER2-VLDLR: 
Neuroblasts 
Reelin:Mitral cells 
of the OB 
D´Arcangelo 
et al., 1999; 
Hack et al., 
2002; Simó et 
al., 2007 
Prokineticin2 PK2/Prokr2 
Cell detachment, 
radial migration in 
OB 
Prokr2: OB  
Glomerular layer 
PK2: OB  Glomerular 
layer 
Ng et al., 
2004; Prosser 
et al., 2007 
(*+) Increase cell proliferation, (*-) Decrease cell proliferation 
Table 1. Regulation of NSCs proliferation and neuroblast migration in the SVZ-RMS 
pathway. 
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2.2.2.10 Radial migration in the OB: Reelin, Tenascin-R and Prokineticin2 as detachment 
signals 
After completing chain migration through the RMS, neuroblasts finally arrive to the OB, where 
a shift in migration occurs, from a tangential to radial direction. To accomplish this cellular 
step, a neuroblast detachment signal is required. The most described ligand-receptor complex 
involved in this process is reelin/ApoER2-VLDLR. Reelin is an ECM secreted glycoprotein 
expressed in mitral cells of the OB. The surface receptors for reelin are the apolipoprotein E 
receptor 2 (ApoER2) and the very low-density lipoprotein receptor (VLDLR), both expressed 
in migrating neuroblasts. To allow the migratory switch, binding of reelin to its receptors 
induces phosphorylation of the intracellular adaptor protein disabled-1 (Dab1) and Src family 
kinases (SFK) (D´Arcangelo et al., 1999, Hiesberger et al., 1999). 
In vitro, SVZ explants supplemented with reelin exhibit a loss of neuroblast chain formation, 
which gives raise to individual cell migration. Furthermore, in vivo observations of reeling-
null mice reveal that neuroblasts fail to migrate radially in the OB and remain in clusters 
(Hack et al., 2002). Additionally, the experimental overexpression of reelin by grafting reelin-
expressing cells in the SVZ produces a dispersion of neuroblasts around the ventricular 
structures by chemokinetic activity and detachment (Courtes et al., 2011).  
Recently, another function of reelin has been hypothesized. It was demonstrated that reelin 
expression is reactivated after brain injury (focal demyelinization of corpus callosum) in 
mature neurons at the proximal damaged area. It is suggested that reelin enhances 
chemoattraction exerted by lesion-derived cytokines that contribute to neuroblast 
recruitment in the boundary of the damaged area. All together, these results support reelin’s 
performance as a detachment and migration key factor (Courtes et al., 2011).  
There are other molecules involved in radial migration in the OB; one of these molecules is 
tenascin-R, an ECM glycoprotein expressed in the granular layer of the OB, where it initiates 
neuroblast chain detachment and radial migration. Tenascin-R-null mutant mice show a cell 
reduction in the granular layer, whereas neuroblasts remain in clusters in the OB 
(Saghatelyan et al., 2004).  
Finally, other molecule involved in OB migration is Prokineticin2 (PK2), which is expressed 
in the granular and periglomerular layers of the OB and acts as detachment signal and 
chemoattractant. PK2 receptor-null mice (Prokr2) exhibit a decrease in the volume of the OB 
and have an abnormal accumulation of neuroblasts around the olfactory ventricle. This 
suggests a deficiency in neuroblast migration and defects in chain migration detachment 
(Prosser et al., 2007). Furthermore, in vitro, SVZ explants co-cultured with cells obtained 
from the glomerular layer of the OB, begin cell migration toward the glomerular layer of the 
explants; whereas cells from the glomerular layer of PK2-null mice do not exhibit 
chemotactic activity (Ng et al., 2005).  
3. Growth factors as an endogenous approach for neurorepair therapy 
3.1 Endogenous response after stroke 
We just described in the previous section the existence of a substantial number of molecules 
and its complex signaling regulating PMD response at the SVZ under basal conditions. 
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However, studies also reveal that neurogenesis could be triggered secondary to specific 
injury conditions, including stroke. Focal cerebral ischemia promotes neurogenesis in the DG 
of the hippocampus and in the SVZ (Arvidsson et al., 2002; Jin et al., 2001; Liu et al., 1998; 
Parent et al., 2002; Zhang et al., 2001); both being a feature shared by rodent and the human 
brain (Jin et al., 2006; Martí-Fabregas et al., 2010). Moreover, these studies demonstrate that the 
default migratory pathway, followed by neuron precursors from the SVZ that supply the OB 
region, can be partially diverted to other destinations including the striatum and cortex after 
stroke injury. Recently, it was demonstrated that stroke enhances long-term neurogenesis, 
although, decreased in magnitude when compared to the acute phase (Thored et al., 2006). 
These findings are of paramount relevance for their therapeutic potential in the field of 
neuronal damage reestablishment, by taking advantage of an endogenous cell source. 
However, Ardvisson et al., in their seminal work, determined that within 6 weeks of transient 
focal stroke uniquely 0.2% of newborn neurons from the SVZ were integrated in the damaged 
striatum. Thus, neurogenesis occurring after cerebral ischemia represents an insufficient cell 
source for the purpose of neuronal replacement therapy (Ardvisson et al., 2002).  
3.2 Self-renewal induced by growth factors: The endogenous neuronal repair 
The rationale for self-renewal induced by growth factors relies on the existence of 
neurogenic niches in the brain with the potential to modulate the proliferative response by 
either injury or growth factors. The purpose of this approach has been to determine whether 
growth factors are able to amplify the endogenous response of NSCs in a meaningful level 
that can account an increase of neuronal differentiation. The concept however, was not new 
in the field of stroke studies. One of us, Dr. James Fallon (Fallon et al., 2000) employed the 6-
hydroxydopamine lesion rodent model of Parkinson’s disease, where he and collaborators 
demonstrated that proliferating cells significantly increased in the striatal SVZ ipsilateral to 
the injured side, however, this increase was exclusive in animals that also received an 
striatal infusion of TGF-; neuroblasts then migrated in mass into the striatum to become 
neurons. 
There is a long and increasing list of growth factors that has the potential to be 
implemented as a therapeutic tool in the recovery process after a stroke event, exploiting 
their neuroprotection and neurogenesis features. Here, we are focusing on studies that 
unveil that growth factors are modifying neurogenesis subsequent to the onset of focal 
cerebral ischemia, specifically in the SVZ-RMS. Table 2 represents a chronological 
compendium of such studies. The hematopoietic factors known to compel neurogenesis 
were omitted in our chapter, nonetheless, they are extensively reviewed by others 
(Greenberg & Jin, 2006). 
The majority of the research described in this section of the chapter employs the most 
common method to study focal stroke, the middle cerebral artery occlusion (MCAO) 
model, which affects the striatum and/or cortex, resembling the injury that commonly 
occurs in stroke patients (Figure 1). To induce this kind of ischemia, an incision in the 
neck is made and after exposition of the common, external and internal carotid arteries, a 
monofilament suture is then carefully introduced via the external carotid artery through 
the lumen of the internal carotid artery until it reaches and occludes the middle cerebral 
artery (MCA).  
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3.2.1 EGF family of growth factors 
It is important to highlight that in practically all the protocols regarding neurogenesis, the 
quintessential strategy to identify newborn cells is the administration of bromodeoxyuridine 
(BrdU), a marker of cell division, which intercalates into the DNA of cells that are 
undergoing proliferation. The neuronal (or glial) lineage of BrdU-labeled cells is determined 
by the co-staining with specific markers of immature or mature phenotypes, which may 
differs depending on the goal of the study. 
3.2.1.1 EGF 
Teramoto and collaborators reported in 2003 the first study about the effect of a growth 
factor on neurogenesis in the SVZ after an ischemic insult (Teramoto et al., 2003). The 
antecedents implicating EGF as a factor that promotes NSCs proliferation and migration 
from the SVZ to the striatum lead them to test if EGF could induce a PMD response in the 
damaged brain after an ischemic event. They administered an intraventricular dose of EGF 
two days after stroke for a period of one week that allow a noteworthy neuronal 
replacement increase after week 13th post MCAO. Interestingly, Teramoto determined that 
the BrdU+/NeuN+ cells observed at the boundary zone of the stroke lesion were not 
DARPP-32 (dopamine and adenosine 3′,5′-monophosphate–regulated phosphoprotein of 
32KD) positive, the prevailing neuronal population in the striatum. Rather than, they found 
65% of the new cells maturated into aspiny parvalbumin-containing (PV) interneurons. This 
effect is intriguing, given the fact that in vitro, EGF stimulates the DARPP-32 phenotype 
(Reynolds & Weiss, 1992). Therefore, albeit EGF is probably directing the mechanisms 
related to neuronal commitment and fate specification, such claims need further study.  
3.2.1.2 Heparin-binding epidermal growth factor-like growth factor (HB-EGF) 
Another member of this family is the HB-EGF that also has a clear effect in increasing 
proliferation of NSCs in the SVZ. However, its effect on migration and differentiation is not 
fully disclosed. In one study, Jin and coworkers analyzed such effect 4 weeks after stroke 
and observed an increase in the number of BrdU cells (approximately 40%) and the number 
of BrdU cells co-localizing with the immature neuronal marker TUC-4 in the SVZ. 
Nonetheless, a concomitant decrease of approximately 60% of neuroblasts (DCX+) 
migrating towards the striatum was also observed. The authors suggested that this effect is 
probably due to its chemoattractant properties. In spite of the decrease in migration, a 
significant improvement in neurological outcome was accounted, probably due to a 
reduction in infarct size promoted by the growth factor (Jin et al., 2004). Later on, another 
study conducted by Sugiura and coworkers determined that recombinant adenovirus-
expressing HB-EGF promotes neurogenesis and angiogenesis in the SVZ. Nonetheless, 
opposite to the study developed by Jin et al., no effect limiting migration of newborn cells 
toward the striatum was reported. Therefore, also in contrast, an increase of neuronal cells 
was observed in the ischemic striatum, going from 2 BrdU+/NeuN+ cells to 23 cells per 
mm2 (Sugiura et al., 2005) Additionally, a functional recovery was observed. The 
discrepancy in both results still remains to be discerned, however, it could be due to the 
different methods employed to deliver the growth factor, which impose differences in 
concentration and availability. 
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3.2.1.3 TGF- 
The first report of TGF's effect on neurogenesis in rats that were subjected to transient 
MCAO, was made by our group (Guerra-Crespo et al., 2009). The majority of stroke studies 
analyze the effect of growth factors in the acute phase of ischemia. However, we were 
interested in the delayed administration of the growth factor, since it resembles the typical 
situation in humans with preexisting stroke injuries, who might benefit from this type of 
therapy. Therefore, we infused TGF directly in the striatum four weeks after injury, when 
the infarction area was no longer expanding and the cellular deterioration had stabilized, 
indicating that the acute phase was completed and the chronic phase had begun.  
Eight weeks after MCAO, and four weeks after the onset of TGF administration, we found 
a 4-fold increase of BrdU labeled cells arising from the ependymal layer and the SVZ. Many 
of the BrdU-labeled cells of the SVZ and others under migration were expressing the 
immature neuronal marker Meis2, a transcription factor that is strongly expressed in striatal 
precursors. Additionally, we found around the site of the infarction about a 7-fold increase 
of BrdU cells that were co-labeled with the neuronal-fate marker NeuN, whereas, several of 
the newborn cells co-labeled with DARPP-32, indicating that they differentiate into striatal 
neurons, which are typical for this brain region. These results indicate that TGF treatment 
significantly increased the yield of neurons produced in the injury response. Although we 
did not examine the long-term survival of these neurons, an approximately 90% of 
behavioral recovery (corner and cylinder test) in the chronic animal suggests that many of 
them became functionally and integrated in the host’s CNS (Guerra-Crespo et al., 2009). 
In the same year, another group (Leker et al., 2009) reported an increase in neurogenesis as 
well as angiogenesis induced by TGF Leker et al., administered an intraparenchymal dose 
of the growth factor 1 day after ischemia, for a consecutive period of 14 days and analyzed 
the long-term response. TGF increased the number of BrdU cells and allow a 2-fold 
increase of neuroblasts in the ischemic hemisphere. Nonetheless, only a slight number of 
newborn neurons in proximity to the infarct border were observed, suggesting that under 
these specific experimental conditions, TGF leads to a moderate but significant neuronal 
differentiation. Concomitant to neurogenesis, TGF expanded (2.4-fold) the area covered by 
blood vessels in the ischemic border zone. The mechanism involved the recruitment of 
endothelial bone marrow-derived cells into newly formed cerebral blood vessels. 
3.2.1.4 Intranasal infusion of TGF
The employment of growth factors in patients is impeded by the facts that intracranial 
infusion is impractical and that many growth factors intravenously administrated are not 
able to cross the blood-brain barrier (BBB). Even though there are methods for bypassing the 
BBB, they typically consist of invasive neurosurgeries that would restrict clinical application 
to the most severe cases.  Noninvasive techniques that are capable of delivering growth 
factors to the CNS represent a therapeutic alternative to surgery. A pioneer work was the 
intranasal administration of neurotrophic growth factor (NGF), which demonstrated that 
delivered growth factors could bypass the BBB. Since then, the prevalence of the intranasal 
administration technique for CNS treatment has grown considerably (Capsoni et al., 2002; 
De Rosa et al., 2005; Frey et al., 1997; Liu et al., 2004; Ma et al., 2008). With this approach of 
administration, therapeutic molecules traverse the BBB through the olfactory pathway and 
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the less-studied trigeminal neural pathway (Thorne et al., 2004). The advantage of this 
method is that factors are delivered directly into the brain and thereby avoid adverse 
systemic effects. The simplicity of the intranasal administration of growth factors makes it 
an outstanding strategy. This non-surgical approach represents a potential therapeutic 
strategy for human patients.  
Based in this knowledge, we delivered an intranasal dose of a pegylated form of TGF 
(PEG-TGF) to make it more stable for the nasal route. We found that intranasal delivery is 
a viable alternative because PEG-TGF was able to induce the proliferation and migration of 
neural progenitors to the damaged striatum (in terms of BrdU incorporation and nestin 
expression), although of less magnitude compared to intracranial TGFadministration. This 
finding is associated with significant behavioral improvement in the MCAO model, 
measured by the corner and cylinder test. Therefore, intranasal delivery of PEG-TGFholds 
great therapeutic potential. 
3.2.2 FGF-2 
From the FGF family, FGF-2 is the member which neurogenic properties have been 
demonstrated. The first study, performed in 2003, reported that, regardless of a 30% increase 
of BrdU+/DCX+ cells, no BrdU+/NeuN+ cells were observed (Wada et al., 2003). In the same 
year, Matsuoka and collaborators also reported an increase (2.1 fold) of BrdU+ cells in the SVZ 
of a global ischemia rodent model, through FGF-2 gene delivery by an adenoviral vector. 
Although neuronal differentiation in the striatum was not analyzed, a small number of 
newborn cells (3%) were labeled positive for NeuN amongst the different layers of the cortex 
and by the proximity to the SVZ suggesting that such cells were derived from the SVZ 
(Matsuoka et al., 2003). Matsuoka’s research set a precedent on gene therapy field, since was 
the first time that a growth factor was administered through viral vector in a stroke model  
Both former works were focused on the study of acute phase of stroke, where a short 
infusion period of the growth factor or a short time analysis after the growth factor- 
adenovirus transduction was made. More recently, Leker and coworkers employed an 
ischemia model with predominant cortical damage and an adenovirus delivery system that 
allowed overexpression of FGF-2 for a long time period. They were able to observe that 
FGF-2 increased proliferation and migration from the SVZ and that the immature neurons 
were localized in the border of damaged cortex when analyzed at 30 and 90 days after 
stroke. Additionally, the results shown that the group treated with FGF-2 presented a 2-fold 
increase of newborn cells expressing NeuN and even a higher increase (22 versus 1.6%) of 
cells labeled with the immature neuronal marker Hu. In either Matsuoka et al., or Leker et 
al., studies, no lineage analyses was performed to asseverate without a doubt, that such cells 
were originated in the SVZ, since they could be also produced in the cortex. Nevertheless, 
the evidence suggests that the majority of the cells arose from the SVZ (Leker et al., 2007). 
The previous studies disclose the enhancement achieved on endogenous neurogenesis in the 
SVZ when EGF or FGF-2 are administered independently. However, a more interesting fact 
would be to analyze the simultaneous effect of both growth factors in order to increase 
neurogenesis. Nakatomi et al., in a breakthrough work addressed that question in a transient 
ischemia model with specific pyramidal hippocampal damage. The results demonstrated 
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that endogenous proliferation and migration are enhanced by intraventricular co-
administration of growth factors after stroke. However, that the growth factor induced 
neuronal regeneration of approximately 40% of the CA1 pyramidal layer, one month after 
stroke, was a remarkable finding (Nakatomi et al., 2002). This study was centered in the 
analysis of the hippocampus; however, only a few years later, Baldauf and Reymann 
examined the combined effect of EGF/FGF-2 on the SVZ. They observed an increase (almost 
double) in the number of BrdU+/DCX+ cells in the ipsilateral striatum, in spite of a 
concomitant increase in the infarct volume. Unfortunately, neuronal fate and behavior were 
not analyzed; therefore, further analyses are required to conclusively discern the effect of 
the synchronic administration of EGF and FGF-2 for striatum neuronal replacement 
(Baldauf and Reymann 2005). 
3.2.3 Neurotrophic factors: BDNF 
The neuroprotective effects of the intraventricular infusion of BDNF after global ischemia were 
reported for the first time in 1994 (Beck et al., 1994). However, the role of BDNF in 
neurogenesis was recently demonstrated. In one report (Gustafsson et al., 2003), BDNF 
expression was successfully attained in the substantia nigra by means of an adenovirus; the 
objective was to transport BDNF anterogradely to the striatum and avoid damage in its 
cytoarchitecture. The transduction of the viral vector took place 4 to 5 weeks prior to the 
MCAO. With this strategy, they found a significant increase of neuroblast migration towards 
the striatum at 2 weeks after ischemia. Additionally, a higher number of BrdU cells co-laballed 
with early neuronal marker Hu and striatal neuronal marker Meis2 were observed. The 
significant relevance for replacement therapy cannot be established with these findings, 
because the transduction of the viral vector generated anomalous behavior patterns and 
therefore, the behavioral outcome cannot be correctly analyzed. Moreover, the high expression 
levels of BDNF aggravated the cellular death of cholinergic, PV and neuropeptide Y 
interneurons in the striatum, which could override the neuroprotective effects observed in 
former studies performed by the same research group (Andsberg et al., 2002). 
Some years later, in another attempt to determine the effect of BDNF on neurogenesis, 
Schavitz and coworkers induced a parietal cortical lesion, and after an intravenous injection 
of BDNF on the following 5 days, were able to observe precursor cells rising from the SVZ 
that were migrating toward the ipsilateral striatum. A substantial number of neuroblasts 
were recruited to the ischemic hemisphere 37 days after the last injection; still, neuronal 
replacement was not observed with this paradigm of cortical injury, since no 
BrdU+/NeuN+ cells were observed. Additionally, the authors were unable to detect cortical 
neurogenesis (Schavitz et al., 2007).  
In summary, a variety of growth factors have been tested in experimental stroke models and 
irrespective of their nature, practically all of them can induce proliferation on NSCs that 
reside in the SVZ. Most of them, enhance in a parallel fashion the recruitment of neuroblasts 
toward the peri-infarcted area, either striatum or cortex. However, extensive differences in 
neuronal differentiation have been observed in the damaged area (even when employing 
the same growth factor), ranging from a highly significant increase to a decrease in 
differentiation levels. The behavioral outcome, measured as an indirect index of functional 
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integration, has been analyzed only in the minority of the studies, finding an important level 
of recovery in some of them.  
The potential of growth factors for endogenous cell replacement is evident; however, clinical 
studies are not currently being undertaken, given the fact that growth factors encompass a 
strong and dangerous mitogenic effect. 
 
Growth 
factor 
Stroke Model 
Delivery 
Method 
Time period 
of infusion 
Effect on 
Neurogenesis 
Behavioral 
outcome 
Reference 
EGF Family
EGF 
Mouse Left 
MCAO 
Minipump in 
lateral ventricle
21 days after 
ischemia for 7 
days 
- 65% of new PV 
interneurons 13 
weeks after stroke 
- 100 fold of 
neuronal 
replacement 
NA 
Teramoto 
et al., 2003 
HB- 
EGF 
Rat Right MCAO
Minipump in 
lateral ventricle
24 hours after 
ischemia for 3 
days 
- Increase of BrdU+ 
cells expressing 
TUC-4 
-60% decrease in 
migrating 
neuroblasts 4 weeks 
after stroke 
Improvement 
in neurological 
score 
Jin et al., 
2004 
HB- 
EGF 
Rat Left MCAO 
Adenoviral 
vector in lateral 
ventricle 
3 days after 
ischemia 
- 2-fold increase of 
vascular density 
(angiogenesis) 
- Increase of 
BrdU+/NeuN+ cells 
(2 vs 23 cells per 
mm2) 28 days after 
ischemia 
Improvement 
in rotarod test 
Sugiura et 
al., 2005 
TGF Rat Left MCAO Minipump in 
striatum 
1 month after 
ischemia for 
28 days 
(chronic 
treatment) 
- 4-fold increase of 
BrdU+ cells 
- 7-fold increase of 
BrdU+/NeuN+ cells 
and several 
BrdU+/DARPP-32+ 
two months after 
stroke 
90% of 
improvement 
in corner and 
cylinder test 
Guerra-
Crespo et 
al., 2009 
TGF Mouse Left 
MCAO 
Minipump 
intra-
parenchyma 
1 day after 
ischemia for 
14 days 
- 2.4 fold increase in 
blood vessel cover 
area in the infarct 
border 
- Small number of 
newborn neurons in 
the infarct border 90 
days post-infusion 
NA 
Leker et al., 
2009 
TGF Rat Left MCAO Intranasal 
delivery 
4 intranasal 
doses per 
month (1 per 
week) 
- Increased BrdU+ 
cells in SVZ and 
ischemic striatum 
- Increased 
neurogenesis 
(BrdU+/Nestin+ 
cells) in the peri-
infarcted striatum 
50% of 
improvement 
in corner and 
cylinder test 
Guerra-
Crespo et 
al., 2010 
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Growth 
factor 
Stroke Model 
Delivery 
Method 
Time period 
of infusion 
Effect on 
Neurogenesis 
Behavioral 
outcome 
Reference 
EGF Family
FGF-2 
(bFGF) 
Rat Right MCAO 
(cortex) 
Intracisternal 
injection 
Injections 24 
and 48 hrs 
after stroke 
- 30% increase of 
BrdU+/DCX+ cells 
at day 7 and 2% at 
day 21 
- No BrdU+/NeuN+ 
cells 
NA 
Wada et al., 
2003 
FGF-2 
Gerbil Global 
ischemia 
Adenoviral 
vector in lateral 
ventricle 
Transduction 
3 hrs after 
stroke 
- 2.1 fold increase of 
BrdU+ cells in the 
SVZ 7 days after 
ischemia 
- 3% of 
BrdU+/NeuN+ in 
cortex 30 days post-
stroke 
NA 
Matsuoka 
et al., 2003 
FGF-2 
Hypertensive Rat 
MCAO (cerebral 
cortex) 
Adenoviral 
vector in the 
infarct border 
Transduction 
starting the 
same day of 
ischemia 
(chronic 
treatment) 
- Increase of BrdU+ 
cells expressing 
neural transcription 
factors MASH1 and 
Pax6 in the peri-
infarcted area 30 
days after stroke 
- Increase of 
BrdU+/Hu+ cells 
(22% vs 1.6%) 
Improvement 
in motor 
disability score 
Leker et al., 
2007 
FGF-2+ 
EGF 
Rat Left MCAO 
Minipump in 
lateral ventricle
10 min after 
ischemia for 
14 days 
- Increased 
proliferation in the 
striatum 
- 2 fold increase of 
BrdU+/DCX+ cells 
in striatum 14 days 
after stroke 
NA 
Baldauf et 
al., 2005 
Neurotrophin
BDNF Rat MCAO 
Adenoviral 
vector in SN  
transported 
anterogradely 
towards 
striatum 
5 weeks 
previously to 
MCAO 
- Increased 
neuroblasts (DCX+)  
- Increased neuronal 
death in the striatum
- Increased 
BrdU+/Meis2+ cells 
2 weeks post-
ischemia 
Vector-induced 
abnormal 
motor behavior 
Gustafsson 
et al., 2003 
BDNF 
Rat 
Photothrombotic 
ischemia  
(cortical stroke) 
Intravenous 
injection 
1 hour post-
ischemia 2nd to 
5th day 
- Highly significant 
increase of 
neuroblasts in 
striatum 37 days 
after last injection 
- No BrdU+/NeuN+ 
cells 
Improvement 
in neurological 
score and 
adhesive tape 
removal test 
Schavitz et 
al., 2007 
Table 2. Growth factors induce SVZ neurogenesis in ischemic stroke. 
4. NSCs transplant therapy: A new expectation 
Neural transplantation is a promising strategy for treatment of several CNS pathologies that 
offers long-lasting improvement and the prospect of permanent cure. The most obvious 
possibility is to use neural transplantation as a technique for cell replacement therapy 
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whereby the cells would occupy the place or the function of dead or degenerated cells. 
Potential advantages to this approach may include greater control over cell fate, the ability 
to deliver any desired number of cells, and reduced risks associated with mitogen infusion. 
A number of different cell types have been considered for cell transplantation with goals 
ranging from replacement of host circuitry to delivery of neuroprotective or 
immunomodulatory compounds.  
The majority of studies to date have shown relatively limited cell replacement from 
endogenous NSCs. Further, the technology for mobilizing endogenous NSCs is relatively 
new. In contrast, work has been in progress for decades to replace lost neural cells by 
transplantation of either fetal brain tissue or more recently, NSCs.  
Recent studies have highlighted the enormous potential of cell transplantation therapy for 
stroke. In this branch of the chapter, we will describe the experimental trials that utilized 
NSCs in the MCAO model, which placed the stepping stone for the first human trials of 
NSCs transplant therapy. 
Fetal brain tissue transplants have been shown to produce some recovery in animal models 
of stroke (Mattsson et al., 1999; Nishino et al., 2000; Riolobos et al., 2001), but ethical 
considerations and a short supply of human fetal tissue limited this approach. As a result, a 
variety of cell types have been tested in stroke models, they include human bone marrow 
cells, human umbilical cord blood cells (Chen et al., 2001a; Chen et al., 2001b; Savitz et al., 
2002; Zhao et al., 2002), rat trophic factor-secreting kidney cells (Mattsson et al., 1999; 
Nishino et al., 2000; Riolobos et al., 2001; Savitz et al., 2002), and immortalized cell lines such 
as the human neuron-like NT2N (hNT) cells (Borlongan et al., 1998; Saporta et al., 1999) and 
MHP36, an embryonic murine immortalized neuroepithelial cell line (Modo et al., 2002; 
Veizovic et al., 2001). In spite of the vast types of transplanted cells employed, they yet need 
to demonstrate a significant behavioral recovery in animal models of stroke and a long-
lasting survival of the grafted tissue (Table 3). 
From the previously mentioned cell types employed for transplant, human cells that have 
been used in these studies fall into 3 categories: A) Neural stem/progenitor cells (NPCs) 
cultured from fetal tissue; B) immortalized neural cell lines, hematopoietic/endothelial 
progenitors and stromal cells isolated from bone marrow, umbilical cord blood, peripheral 
blood or C) adipose tissue. Even though transplanted human cells have shown promise, 
other sorts of cells have arisen to address the need for a quintessential cell source for 
transplant therapy. 
Amongst them, NSCs have been proposed as a potential source of new cells to replace those 
lost due to central nervous system injury such as stroke, as well as a source of trophic 
molecules to minimize damage and promote recovery in clinical trials. 
In the background of this imperative clinical need, hundreds of studies have recently 
published the therapeutic potential of either endogenous or transplanted NSCs in laboratory 
models of stroke. To their advantage, NSCs have the capacity to respond actively to their 
environment, migrate to areas of injury, and secrete neuroprotective compounds. Such 
properties may afford them therapeutic potential both in the acute phase and at later time 
points when the employment of conventional medical therapies would no longer be 
effective. 
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NSCs can be isolated from many regions of the CNS of embryonic as well as adult 
mammals. As mentioned in other section of the chapter, they can be propagated in culture 
in the presence of EGF and/or FGF-2 as proliferative clusters of cells termed neurospheres. 
Recent studies have demonstrated that rather than being homogeneous aggregates of stem 
cells, neurospheres actually represent a heterogeneous collection of cells including true stem 
cells, committed progenitors, and differentiated progeny. This is in contrast to embryonic 
stem cells (ESCs), which in the presence of appropriate signaling molecules can be 
maintained as a relatively homogeneous population of stem cells. NSCs also differ from 
ESCs in terms of the variety of neurons they can generate. Profiles of NSCs gene expression 
tend to point to NSCs expanded as neurospheres in EGF and FGF-2 as adopting a forebrain 
profile. 
Consistent with this, attempts to differentiate NSCs into cells from other regions of the CNS, 
such as dopaminergic neurons, cerebellar Purkinje cells, or motoneurons have in most cases 
been unsuccessful. Nevertheless, NSCs can be successfully differentiated into representative 
cell types in parts of the brain most commonly affected by stroke, such as cortical projection 
neurons (Englund et al., 2002), interneurons (Scheffler et al., 2005) and hippocampal 
pyramidal neurons (Corti et al., 2005). Retrograde labeling, synaptic integration, and action 
potential generation from NSCs-derived neurons has been demonstrated in vivo (Englund et 
al., 2002).  
Given the fact that NSCs have the capability to differentiate into neurons (Kelly et al., 2004; 
Song et al., 2002a; Song et al., 2002b), astrocytes (Eriksson et al., 2003; Herrera et al., 1999; 
Winkler et al., 1998), oligodendrocytes (Pluchino et al., 2003; Yandava et al., 1999), and 
perhaps endothelium (Wurmser et al., 2004), advocates that conception that NSCs should be 
capable of replacing most of the cell types affected by an ischemic injury.  
4.1 From theory to practice: NSCs transplant in rodent models of stroke 
Actual results in preclinical studies, however, have been quite varied. NSCs, including 
human, can clearly survive after transplantation, have a tendency to migrate toward areas of 
infarct (Kelly et al., 2004), and can generate functional neurons (Englund et al., 2002) that 
may form connections with host cells (Park et al., 2002). Although several studies have 
found NSCs to predominantly differentiate into glia after transplantation into normally non-
neurogenic regions (Eriksson et al., 2003; Herrera et al., 1999; Winkler et al., 1998), robust 
neural differentiation has been observed after transplantation of cells cultured on laminin 
(Wu et al., 2002; Yan et al., 2007).  
Most studies have not observed substantial changes in infarct size after NSCs 
transplantation (Kelly et al., 2004; Pollock et al., 2006); however, neuroprotective (Lee et al., 
2007; Ourednik et al., 2002) and immunomodulatory (Fujiwara et al., 2004; Pluchino et al., 
2005) effects of NSCs in addition to their potential for at least some cell replacement (Sinden 
et al., 1997), have collectively yielded beneficial effects in multiple animal models of 
neurodegeneration and brain injury, including stroke (Chu et al., 2004; Pollock et al., 2006; 
Sinden et al., 1997). 
NSCs transplantation enhances endogenous cell proliferation in the SVZ and promotes 
angiogenesis in the peri-infarct zone of adult rats, even if it is performed in the acute phase 
of ischemic injury. In addition, this transplanted NSCs managed to survive, migrate, 
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differentiate, and also induce improvement in neurological functions (Zhang et al., 2009a, 
2009b; Zhang et al., 2010). Grafted NSCs enhanced the number of BrdU-positive cells in 
ischemic ipsilateral SVZ at 7 days after transplantation, an effect that persisted to at least 14 
days post-transplantation. These results revealed that NSCs transplantation increases cell 
proliferation in the SVZ and promotes angiogenesis in the peri-infarct zone after focal 
cerebral ischemia in adult rats. The reason that grafted NSCs increase endogenous NSPCs 
proliferation may be due to the production of certain growth factors or repression of 
inflammation and apoptosis. 
In addition to promote proliferation, it has been shown that human fetal striatum derived 
NSCs, transplanted as neurospheres, survive in stroke-damaged rat striatum, migrate 
toward the site of the injury, and differentiate into mature neurons in the absence of tumor 
formation (Darsalia et al., 2007). 
Evidence of cell migration to the site of ischemic injury from administration by various routes 
has been seen, including intravenous, intraarterial, and intraparenchymal brain injection. 
Migration potential may differ according to cell type and route, but this has not been 
systematically explored for most cell lines. Animal studies with a number of NSCs lines have 
shown evidence of cell survival and in some studies improvement in behavioral outcomes 
after focal ischemic injury (Bacigaluppi et al., 2008; Borlongan et al., 1998; Chu et al., 2004; 
Ishibashi et al., 2004; Jiang et al., 2006; Modo et al., 2002; Pollock et al., 2006; Wei et al., 2005).  
In a follow-up work, Darsalia et al. showed that transplantation shortly after stroke (48 
hours) resulted in better cell survival than did transplantation 6 weeks after stroke, but the 
delayed transplantation did not influence the magnitude of migration, neuronal 
differentiation, and cell proliferation in the grafts. Additionally, transplanting greater 
numbers of grafted NSCs did not result in a greater number of surviving cells or increased 
neuronal differentiation. They observed a substantial number of activated microglia 48 
hours after the insult in the injured striatum, but reached maximum levels 1 to 6 weeks after 
stroke (Darsalia et al., 2011). Their findings show that the best survival of grafted human 
NSCs in stroke-damaged brain requires optimum numbers of cells to be transplanted in the 
early post stroke phase, before the inflammatory response is established.  
In an attempt to improve transplant survival and behavioral outcome, Jin et al. found that 
intralesional transplantation of nestin/Sox2-immunopositive neuronal precursor cells 
(NPCs) derived from BG01 human embryonic stem cells 3 weeks after distal MCAO in rats 
reduced infarct volume and improved behavioral outcome 4–9 weeks post-transplant (Jin et 
al., 2010a). In another study, they found that the beneficial effects of transplantation 
occurred in both young adult (3-month-old) and aged (24-month-old) rats (Jin et al., 2010b). 
NPCs express many factors known to influence neurite plasticity and thus have the 
potential to enhance structural plasticity after stroke. With that notion in mind, Andres et al. 
decided to analyze the effects of transplanted NPCs on structural plasticity and axonal 
transport in the ischemic rat brain. They found that NPCs transplant one week after the 
ischemic event enhanced dendritic plasticity in both the ipsi- and contralesional cortex. 
Moreover, stem cell-grafted rats demonstrated increased corticocortical, corticostriatal, 
corticothalamic and corticospinal axonal rewiring from the contralesional side; with the 
transcallosal and corticospinal axonal sprouting correlating with functional recovery 
(Andres et al., 2011). 
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With the advent and enhancement of molecular biology technology, tumor-derived 
neuronal tissues, including immortal teratocarcinoma-derived cells such as NT2N and hNT 
cells have been tested in stroke models (Bacigaluppi et al., 2008; Borlongan et al., 1998). 
Human fetal cortex cells have been immortalized by genetic modification (e.g. insertion of 
transcription factor genes including v-myc (Cacci et al., 2007) and c-myc (Pollock et al., 2006). 
Irrespective of cell type or route of administration, cell survival has been limited. 
Quantification of cell survival is poorly reported. Reports, from the few studies that have 
attempted to quantify cell survival, range from 1% (Hicks et al., 2009) to 30% (Darsalia et al., 
2007). Site of transplantation may be relevant to cell survival, with pathological evidence of 
33.4 ± 6.1% viable cells when human fetal neural stem cells (hNSCs) were transplanted in 
non-ischemic tissue medial to the ischemic lesion (Kelly et al., 2004). In contrast 30–50% of 
hNT cells have been suggested to survive in and around the ischemic tissue (Bliss et al., 
2006). Inflammation following ischemic stroke may aid cell migration (Belmadani et al., 
2006), but a negative correlation between cell survival and inflammatory response has also 
been observed (Kelly et al., 2004), and may be a factor to consider when timing cell 
administration. 
Although transplanted NSCs can recover some of the function lost after stroke, recovery has 
shown to be incomplete and restoration of lost tissue is minimal in most of the cases. The 
challenge set was to provide transplanted cells with matrix support in order to optimize 
their ability to engraft the damaged tissue. Bible et al. demonstrated that plasma 
polymerised allylamine (ppAAm)-treated poly(D,L-lactic acid-co-glycolic acid) (PLGA) 
scaffold particles can act as a structural support for neural stem cells injected directly 
through a needle into the lesion cavity using magnetic resonance imaging-derived 
coordinates. Upon implantation, the neuro-scaffolds integrated efficiently within the rat host 
tissue forming a primitive neural tissue. These work demonstrated that neuro-scaffolds 
could be a more advanced method to enhance brain repair. This study provides a 
substantial step in the technology development required for the translation of this approach. 
Other cell sources employed for this purpose are the induced pluripotent stem (iPS) cell and 
mesenchymal stem cells (MSCs). iPS cells can be produced with high reproduction ability 
and pluripotency to differentiate into various types of cells, making them a feasible resource 
for transplantation, with the additional benefit of obtaining these cells from the same 
patient. On the other hand, MSC are multipotent stem cells that can differentiate into a 
variety of cell types.  
In one study, undifferentiated iPS cells were transplanted into the ipsilateral striatum of a 
MCAO model of stroke; the transplanted iPS cells expanded and formed larger tumors in 
the post-ischemic brain compared with the control condition. iPS cells formed a tridermal 
teratoma (Kawai et al., 2010). Despite this finding, iPS cells are still a hopeful alternative to 
provide neural cells for ischemic brain injury; however, tumor formation still needs to be 
prevented and controlled. 
In another study that employed human bone marrow-derived MSCs (hBMSCs) found a 
significant recovery of behavior in the hBMSCs-treated rats beginning at 14 days after 
MCAO compared with the control animals. High levels of BDNF, neurotrophin-3 (NT-3), 
and VEGF were detected in the hBMSCs-treated brain, as well as an increased proliferation 
of neuronal progenitor cells in the SVZ (Bao et al., 2011). This indicates that it is unlikely that 
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MSCs replaced the damaged tissue and more likely that they secreted trophic factors that 
promoted functional recovery after stroke. 
Altogether, these findings, therefore, placed the stepping stone for direct clinical 
implications. However, evidence indicates that NSCs transplantation may protect the CNS 
from inflammatory damage via a “bystander” mechanism rather than by direct cell 
replacement (Martino & Pluchino, 2006). 
4.2 Human trials with stem cells 
Results of NSCs transplantation in ischemic stroke patients have not been reported, 
although in 2010 ReNeuron, a company in the United Kingdom received an approval to 
start a clinical trial using expanded NSCs. Therefore, we will witness the first clinical results 
of NSCs transplants. Nonetheless, the potential of precursor cells as an exogenous source for 
transplant therapy has been already assessed in some clinical trials (summarized in table 3). 
Neural cells derived from an immortalized human teratocarcinoma cell line (NT2N cells) 
underwent two small clinical studies after showing improved behavioral outcomes in rats 
(Borlongan et al., 1998). In the first human safety study (Stilley et al., 2004), twelve patients 
who had suffered ischemic stroke on average 27 months earlier, received doses of between 2 
and 6 million cells by direct injection into the basal ganglia. No cell related adverse events 
were reported. Some motor improvement was reported in around half the subjects at 6 
months based on one clinical stroke scale and an increase in 18F-flurodeoxyglucose uptake 
on brain positron emission tomography (PET) scans was also reported, although of unclear 
significance. Subsequently Kondziolka and colleagues (Kondziolka et al., 2005) reported on 
an open-label randomized phase II efficacy trial of 5–10 million NT2N cells including 14 
actively treated subjects with stroke between 1 and 6 years earlier. Patients were 
randomized to receive cells with rehabilitation or rehabilitation alone in a 7:2 ratio and two 
ascending dose arms. Ischemic and hemorrhagic stroke formed half of the subjects each. No 
cell related adverse events were noted, and the major adverse events reported (seizure and 
subdural hematoma) were considered to be procedure-related. Neurological motor scores 
that were stable 6 months prior to surgery were reported to improve in 6/14 subjects by 6 
months while in 4/14 subjects the scores deteriorated. There was no indication of any dose-
related effects. 
Savitz and colleagues used the intra-parenchymal route for delivery of fetal porcine derived 
cells in five patients, who suffered stroke 3–10 months prior (Savitz et al., 2005). The study 
was halted after the fourth and fifth patients had worsening motor deficits and seizures. 
Whether cell or procedure related complications were the cause, it still remains unclear. 
Mesenchymal stem cells have been administered intravenous in a controlled trial (Bang et 
al., 2005) and autologous cells have been transplanted intraparenchymally in an open study 
(Suárez-Monteagudo et al., 2009). Neither trial reported any cell or procedure related 
adverse events up to one year follow-up. In the latter study, clinical scores showed minimal 
and insignificant changes. Bang and colleagues reported improvement in one functional 
score of activities of daily living (Barthel index scores measured at 3, 6 and 12 months after 
cell therapy) but not in other clinical measures of outcome (modified-Rankin scale and 
National Institutes of Health Stroke Scale scores) and the number of subjects was small (5 
actively treated and 25 controls). 
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Cell Source Stroke Area 
Time period 
(after transplant) 
Behavioral 
outcome 
Nº of surviving 
cells 
Reference 
NSCs transplant therapy in rodent models of stroke 
Human 
Neuron-Like 
NT2N 
MCAO 24 weeks 
3-fold 
improvement of 
Passive Avoidance 
Test 
NA 
Borlongan et al., 
1998 
Rat Trophic 
Factor-Secreting 
Kidney Cells 
MCAO 20 weeks 
1 point 
augmentation in 
Prehensile Traction 
Test 
NA 
Mattsson et al., 
1999 
Human NT 
Neurons 
MCAO 12 weeks 
50% of behavioral 
improvement in 
functional tests 
24,217 ± 9,260 
Saporta et al., 
1999 
Human 
Umbilical Cord 
Blood Cells 
MCAO 5 weeks 
Two points 
reduction of 
Modified 
Neurological 
Severity Score 
32 600 ± 1689 
Chen et al., 
2001a 
Rat Bone 
Marrow Cells 
MCAO 2 weeks 
50% of behavioral 
improvement in 
functional tests 
14% (Total of 
4×105) 
Chen et al., 
2001b 
MHP36 Human 
Immortalized 
Cell Line 
MCAO 8 weeks 
2-Fold 
improvement in 
Water Maze 
Acquisition Test 
7500 
Veizovic et al., 
2001 
MHP36 Human 
Immortalized 
Cell Line 
MCAO 4 weeks 
30% of behavioral 
improvement in 
functional tests 
7500 
Modo et al., 
2002 
Human Bone 
Marrow Cells 
MCAO 2-6 weeks 
33.5 + 8.7% of 
somatosensory 
asymmetries 
NA Zhao et al., 2002 
Human NSCs 
neurospheres 
Distal MCAO 4 weeks NA 100,147 ± 28,944 Kelly et al., 2004 
CTX0E03 
Human Neural 
Stem Cells 
MCAO 6-12 weeks 
50% of behavioral 
improvement in 
functional tests 
NA 
Pollock et al., 
2006 
iPS cells MCAO 7 weeks None Tumor of 50mm3 
Kawai et al., 
2010 
Human Bone 
Marrow-
Derived 
Mesenchymal 
MCAO 4 weeks 
Decrease of 4 
points in the 
Modified 
Neurological 
Severity Scores 
NA Bao et al., 2011 
NSCs transplant therapy in stroke patients
Cell Source Stroke Area 
Time period 
(after transplant) 
Behavioral 
outcome 
Nº of surviving 
cells 
Reference 
Neural MSCs 
derived 
MCA 48 weeks 
Significant 
improvement for 
12 weeks in Barthel 
Index (30 points 
augmentation) 
NA Bang et al., 2005 
Human 
Neuronal Cells 
NA 96 weeks 
Improvement of 6.9 
points in the 
European Stroke 
Scale at 24 weeks 
NA 
Kondziolka et 
al., 2005 
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Cell Source Stroke Area 
Time period 
(after transplant) 
Behavioral 
outcome 
Nº of surviving 
cells 
Reference 
Neural Fetal 
Porcine Cells 
Basal Ganglia 192 weeks 
Improvement in 
speech, language 
and/or motor 
impairments in 
40% of the patients
NA 
Savitz et al., 
2005 
Bone Marrow 
Stem Cells 
NA 48 weeks None NA 
Suárez-
Monteagudo et 
al., 2009 
Table 3. Experimental and clinical NSCs transplant therapy in stroke. 
4.3 The prospect of NSCs transplant therapy for stroke 
NSCs transplantation therapy for stroke holds great promise. However, the mechanisms of 
recovery are not completely understood. It is very likely that more than one mechanism is 
involved in the processes of recovery, and it still remains to be answered.  
To this end, some standardization of the basic research, especially for behavior, is needed so 
that direct comparisons can be made between studies. Furthermore, longer-term studies are 
required to determine whether the cell-enhanced recovery is sustained and also to 
determine the tumorigenic potential of the cells. Other challenges include ensuring 
appropriate characterization, manufacturing, and quality control of transplanted cells and 
rigorous testing of viral and adventitious agents. Clearly, more research is needed to 
understand the bidirectional interaction between the transplanted cells and the host to 
optimize the chances of success before proceeding to the clinic.  
Although reconstructing normal brain circuitry following stroke via NSCs is not likely in the 
foreseeable future, and although great care must be taken to ensure safety before 
considering clinical trials, preliminary evidence supports the therapeutic potential of NSCs 
for treatment of ischemic brain injury in animal models. 
Understanding the mechanism of action of human NPCs in the post-ischemic brain will be 
important for the successful translation of cell transplantation strategies to the clinic. For 
example, if modulation of host brain plasticity is a major human NPCs mechanism of action, 
this could dictate the best time to transplant cells after stroke; “network relearning” occurs 
within weeks of stroke and continues for several months, making it a good therapeutic target 
with a large time window of intervention. Furthermore, knowing what changes the human 
NPCs elicit in the brain offers useful surrogate indicators of transplanted cell activity. 
5. Conclusions 
Under normal and pathological conditions, the adult brain is able to preserve regions with 
regenerative potential. Current research of neurogenic niches is revealing their complex 
homeostatic process, but at the same time, is bestowing with expectation that unraveling the 
characteristics of the unique molecular environment of the SVZ and the understanding of 
the underlying mechanisms that regulate the creation of new neurons in the adult brain will 
allow us to manipulate NSCs to yield a significant number of neurons capable of integration 
into human functional brain circuitries that were damaged and improve the motor deficits 
secondary to stroke or neurodegenerative diseases.  
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Long-term studies reviewed here support the persistence of an attenuate plasticity process 
residing within the neurogenic SVZ and RMS throughout life, which can be modulated in 
major extent by the action of some growth factors. The employment of growth factors could 
circumvent the technical and ethical constraints by using stem cells for transplant therapy. 
In addition, autologous transplantation of NSCs expanded in vitro could also avoid these 
concerns, and for this reason, it can be considered as a promising alternative. The first 
transplant of NSCs in stroke patients is currently in progress.  
Altogheter, the large body of evidence supports the manipulation of endogenous NSCs and 
employment of grafted stem cells as future treatments for acute and chronic stroke. In spite 
of current efforts, the effectiveness and safety of both approaches are still being developed. 
It is clear that further investigation is necessary before such methods can be applied for 
human treatment and in our opinion, successful cell therapy for stroke patients, is still in a 
distant future. 
6. Acknowledgments 
We thank to Diana Millán-Aldaco and Marcela Palomero-Rivero for their relevant critical 
input on the manuscript. This work was supported by IMPULSA of the Universidad 
Nacional Autónoma de México (UNAM); by the Iniciativa de Apoyo complementario a la 
realización de las obras determinadas (IACOD), UNAM Grant No. I1201911 and by 
Programa de Apoyo a Proyectos de Investigación e Innovación Tecnológica (PAPIIT), 
UNAM Grant No. IN225209-3. 
7. References 
Altman, J. (1963) Autoradiographic investigation of cell proliferation in the brains of rats 
and cats. The Anatomical record, 145: 573–91. 
Altman, J., Das, G.D. (1965) Autoradiographic and histological evidence of postnatal 
hippocampal neurogenesis in rats. J Comp Neurol., 124:319–335. 
Altman, J. (1969) Autoradiographic and histological studies of postnatal neurogenesis IV. 
Cell proliferation and migration in the anterior forebrain, with special reference to 
persisting neurogenesis in the olfactory bulb. J Comp Neurol., l137:433–458. 
American Heart Association. (2007) International Cardiovascular Disease Statistics; 
www.americanheart.org.  
Andres, R.H., Horie, N., Slikker, W., Keren-Gill, H., Zhan, K., Sun, G., Manley, N.C., Pereira, 
M.P., Sheikh, L.A., McMillan, E.L., Schaar, B.T., Svendsen, C.N., Bliss, T.M., 
Steinberg, G.K. (2011) Human neural stem cells enhance structural plasticity and 
axonal transport in the ischaemic brain. Brain, 134:1777-1789. 
Andsberg, G., Kokaia, Z., Klein, R.L., Muzyczka, N., Lindvall, O., Mandel, R.J. (2002) 
Neuropathological and behavioral consequences of adeno-associated viral vector-
mediated continuous intrastriatal neurotrophin delivery in a focal ischemia model 
in rats. Neurobiol Dis., 9:187-204. 
Anton, E.S., Ghashghaei, H.T., Weber, J.L., McCann, C., Fischer, T.M., Cheung, I.D., 
Gassmann, M., Messing, A., Klein, R., Loyd, K.C.K., Lai, C. (2004) Receptor tyrosine 
kinase ErbB4 modulates neuroblast migration and placement in the adult forebrain. 
Nat Neurosci., 7:1319-1328. 
www.intechopen.com
 
Neural Stem Cells: Exogenous and Endogenous Promising Therapies for Stroke 
 
329 
Arvidsson, A., Collin, T., Kirik, D., Kokaia, Z., Lindvall, O. (2002) Neuronal replacement 
from endogenous precursors in the adult brain after stroke. Nat Med., 8:963-70. 
Bacigaluppi, M., Pluchino, S., Martino, G., Kilic, E., Hermann, D.M. (2008) Neural 
stem/precursor cells for the treatment of ischemic stroke. J Neurol Sci., 265:73-77. 
Baldauf, K., Reymann, K.G. (2005) Influence of EGF/bFGF treatment on proliferation, early 
neurogenesis and infarct volume after transient focal ischemia. Brain Res., 1056:158-
167.  
Balenci, L., Saoudi, Y., Grunwald, D., Deloulme, J.C., Bouron, A., Bernards,  A., Baudier, J. 
(2007) IAGAP1 regulates adult neural progenitors  in vivo and vascular endothelial 
growth factor-triggered neural  progenitor migration in vitro. J Neurosci., 27:4716–
4724. 
Bang, O.Y., Lee, J.S., Lee, P.H, Lee, G. (2005) Autologous mesenchymal stem cell 
transplantation in stroke patients. Ann Neurol., 57:874-882. 
Bao, X., Wei, J., Feng, M., Lu, S., Li, G., Dou, W., Ma, W., Ma, S., An, Y., Qin, C., Zhao, R.C., 
Wang, R. (2011) Transplantation of human bone marrow-derived mesenchymal 
stem cells promotes behavioral recovery and endogenous neurogenesis after 
cerebral ischemia in rats. Brain Res., 1367:103-113. 
Bath, K.G., Mandairon, N., Jing, D., Rajagopal, R., Kapoor, R., Chen, Z.Y., Khan, T., Proenca, 
C.C., Kraemer, R., Cleland, T.A., Hempstead, B.L., Chao, M.V., Lee, F.S. (2008)  
Variant  brain-derived  neurotrophic  factor  (Val66Met)  alters adult olfactory bulb 
neurogenesis and spontaneous olfactory discrimination. J Neurosci., 28:2383–2393. 
Battista, D., Rutishauser, U. (2010) removal of polysialic acid triggers dispersion of 
subventricularly derived neuroblasts into surrounding CNS tissues. J Neurosci., 
11:3995– 4003. 
Belluardo, N., Mudó, G., Bonomo, A., Di Liberto, V., Frinchi, M., Fluxe, K. (2008). Nicotine 
induced fibroblast growth factor-2 restores the age-related decline of precursor cell 
proliferation in the subventricular zone of rat brain. Brain Res., 1193:12-24. 
Belluzzi, O., Benedusi, M., Ackman, J., LoTurco, J.J. (2003) Electrophysiological 
differentiation of new neurons in the olfactory bulb. J Neurosci., 23, 10411–10418. 
Belmadani, A., Tran, P.B., Ren, D., Miller, R.J. (2006) Chemokines regulate the migration of 
neural progenitors to sites of neuroinflammation. J Neurosci., 26:3182-3191. 
Belvindrah, R., Hankel, S., Walker, J., Patton, B.L., Müller, U. (2007) Integrins Control the 
Formation of Cell Chains in the Adult Rostral Migratory Stream. J Neurosci., 
27:2704–2717. 
Benraiss, A., Chmielnicki, E., Lerner, K., Roh, D., Goldman, S.A. (2001) Adenoviral brain-
derived neurotrophic factor induces both neostriatal and olfactory neuronal 
recruitment from endogenous progenitor cells in the adult forebrain. J Neurosci., 21, 
6718–6731. 
Bible, E., Chau, D.Y., Alexander, M.R., Price, J., Shakesheff, K.M., Modo, M. (2009) The 
support of neural stem cells transplanted into stroke-induced brain cavities by 
PLGA particles. Biomaterials., 30:2985-9294. 
Bliss, T.M., Kelly, S., Shah, A.K., Foo, W.C., Kohli, P., Stokes, C., Sun, G.H., Ma, M., Masel, J., 
Kleppner, S.R., Schallert, T., Palmer, T., Steinberg, G.K. (2006) Transplantation of 
hNT neurons into the ischemic cortex: cell survival and effect on sensorimotor 
behavior. J Neurosci Res., 83:1004-1014. 
www.intechopen.com
 
Neural Stem Cells and Therapy 
 
330 
Borlongan, C.V., Tajima, Y., Trojanowski, J.Q., Lee, V.M., Sanberg, P.R. (1998) 
Transplantation of cryopreserved human embryonal carcinoma-derived neurons 
(NT2N cells) promotes functional recovery in ischemic rats Exp. Neurol. 149:310–
321. 
Brose, K., Tessier-Lavigne, M. (2000) Slit proteins: key regulators of axon guidance, axonal 
branching, and cell migration. Curr Opin Neurobiol., 10:95–102. 
Burns, T.C., Rodriguez, G.J., Patel, S., Hussein, H.M., Georgiadis, A.L., Lakshminarayan, K., 
Qureshi, A.I. (2008) Endovascular interventions following intravenous 
thrombolysis may improve survival and recovery in patients with acute ischemic 
stroke: a case control study. Am J Neuroradiol., 29:1918-1924. 
Cacci, E., Villa, A., Parmar, M., Cavallaro, M., Mandahl, N., Lindvall, O., Martinez-Serrano, 
A., Kokaia, Z. (2007) Generation of human cortical neurons from a new immortal 
fetal neural stem cell line. Exp Cell Res., 313:588-601. 
Capsoni, S., Giannotta, S., Cattaneo, A. (2002) Nerve growth factor and galantamine 
ameliorate early signs of neurodegeneration in anti-nerve growth factor mice. Proc 
Natl Acad Sci USA, 99:12432-7. 
Carleton, A., Petreanu, L.T., Lansford, R., Alvarez-Buylla, A., Lledo, P.M. (2003) Becoming a 
new neuron in the adult olfactory bulb. Nat Neurosci., 6:507–518. 
Chazal, G., Durbec, P., Jankovski, A., Rougon, G., Cremer, H. (2000) Consequences of neural 
cell adhesion molecule deficiency on cell migration in the rostral migratory stream 
of the mouse. J Neurosci., 20:1446–1457.  
Chen, J., Li, Y., Wang, L., Lu, M., Zhang, X., Chopp, M. (2001b) Therapeutic benefit of 
intracerebral transplantation of bone marrow stromal cells after cerebral ischemia 
in rats. J. Neurol. Sci., 189:49–57. 
Chen, J., Sanberg, P.R., Li, Y., Wang, L., Lu, M., Willing, A.E., Sanchez-Ramos, J., Chopp, M. 
(2001a) Intravenous administration of human umbilical cord blood reduces 
behavioral deficits after stroke in rats. Stroke, 32:2682–2688. 
Chiaramello, S., Dalmasso, G., Bezin, L., Marcel, D., Jourdan, F., Peretto, P., Fasolo, A., De 
Marchis, S.  (2007) BDNF/TrkB interaction regulates migration of SVZ precursor 
cells via PI3-K and MAP-K signalling pathways. Eur J Neurosci., 26:1780–1790. 
Chojnacki, A.K., Mak, G.K., Weiss, S. (2009) Identity crisis for adult periventricular neural 
stem cells: subventricular zone astrocytes, ependymal cells or both?. Nat Rev 
Neurosci., 10:153-63.Chu, K., Kim, M., Park, K.I., Jeong, S.W., Park, H.K., Jung, K.H., 
Lee, S.T., Kang, L., Lee, K., Park, D.K., Kim, S.U., Roh, J.K. (2004) Human neural 
stem cells improve sensorimotor deficits in the adult rat brain with experimental 
focal ischemia. Brain Res., 1016:145–153. 
Conover, J.C., Doetsch, F., Garcia-Verdugo, J.M., Gale, N.W., Yancopoulos, G.D., Alvarez-
Buylla, A. (2000) Disruption of Eph/ephrin signaling affects migration and 
proliferation in the adult subventricular zone. Nat Neurosci., 3:1091-1097. 
Corti, S., Locatelli, F., Papadimitriou, D., Donadoni, C., Del Bo, R., Fortunato, F., Strazzer, S., 
Salani, S., Bresolin, N., Comi, G.P. (2005) Multipotentiality, homing properties, and 
pyramidal neurogenesis of CNS-derived LeX(ssea-1)_/CXCR4_ stem cells. FASEB 
J., 19:1860 –1862. 
Courtès, S., Vernerey, J., Pujadas, L., Magalon, K., Cremer, H., Soriano, E., Durbec, P., Cayre, 
M. (2011) reelin controls progenitor cell migration in the healthy and pathological 
adult mouse brain. PLoS ONE, 6:e20430. 
www.intechopen.com
 
Neural Stem Cells: Exogenous and Endogenous Promising Therapies for Stroke 
 
331 
Cowan, C.A., Henkemeyer, M. (2002). Ephrins in reverse, park and drive. Trends Cell Biol., 
12: 339–346. 
Craig, C.G., Tropepe, V., Morshead, C.M., Reynolds, B.A., Weiss, S., van der Kooy, D. (1996) 
In vivo growth factor expansion of endogenous subependymal neural precursor 
cell populations in the adult mouse brain. J Neurosci., 16:2694-2658. 
Cremer, H., Lange, R., Christoph, A., Plomann, M., Vopper, G., Roes, J., Brown, R., Baldwin, 
S., Kraemer, P., Scheff, S., Barthels, D., Rajewsky, K., Wille, W. (1994) Inactivation of 
the N-CAM gene in mice results in size reduction of the olfactory bulb and deficits 
in spatial learning. Nature, 367:455–459. 
D’Arcangelo, G., Miao, G.G., Chen, S.C., Soares, H.D., Morgan, J.I., Curran, T. (1995) A 
protein related to extracelular matrix proteins deleted in the mouse mutant reeler. 
Nature, 374:719–723. 
Darsalia, V., Kallur, T., Kokaia, Z. (2007) Survival, migration and neuronal differentiation of 
human fetal striatal and cortical neural stem cells grafted in stroke-damaged rat 
striatum. Eur J Neurosci., 26:605–14. 
Darsalia, V., Allison, S.J., Cusulin, C., Monni, E., Kuzdas, D., Kallur, T., Lindvall, O., Kokaia, 
Z. (2011) Cell number and timing of transplantation determine survival of human 
neural stem cell grafts in stroke-damaged rat brain. J Cereb Blood Flow Metab., 
31:235-42.  
Dawson, M.R., Polito, A., Levine, J.M., Reynolds, R. (2003) NG2-expressing glial progenitor 
cells: an abundant and widespread population of cycling cells in the adult rat CNS. 
Mol Cell Neurosci., 24:476–488. 
De Rosa, R., Garcia, A.A., Braschi, C., Capsoni, S., Maffei, L., Berardi, N., Cattaneo, A. (2005) 
Intranasal administration of nerve growth factor (NGF) rescues recognition 
memory deficits in AD11 anti-NGF transgenic mice. Proc Natl Acad Sci USA, 
102:3811-6. 
De Wit, J., Verhaagen, J. (2003) Role of semaphorins in the adult nervous system. Prog 
Neurobiol.,  71:249-67. 
Dirnagl U. (2006) Bench to bedside: the quest for quality in experimental stroke research. J 
Cereb Blood Flow Metab., 26:1465–1478. 
Doetsch, F., Alvarez-Buylla, A. (1996) Network of tangentially phatways for neuronal 
migration in adult mammalian brain. Proc Natl Acad Sci USA., 93:14895–14900. 
Doetsch, F., Garcia-Verdugo, J. M., Alvarez-Buylla, A. (1997) Cellular composition and 
three-dimensional organization of the subventricular germinal zone in the adult 
mammalian brain. J Neurosci., 17:5046–5061. 
Doetsch, F., Caille, I., Lim, D. A., Garcia-Verdugo, J. M., Alvarez-Buylla, A. (1999) 
Subventricular zone astrocytes are neural stem cells in the adult mammalian brain. 
Cell, 97:703–716.  
Doetsch, F., Petreanu, L., Caille, I., Garcia-Verdugo, J.M., Alvarez-Buylla, A. (2002) EGF 
converts transit-amplifying neurogenic precursors in the adult brain into 
multipotent stem cells. Neuron., 36:1021-1034. 
Drescher, U. (1997) The Eph family in the patterning of neural development. Curr Biol., 
7:799–807.  
Emsley, J.G., Hagg, T. (2003) alpha6beta1 integrin directs migration of neuronal precursors 
in adult mouse forebrain. Exp. Neurol., 183:273–285. 
www.intechopen.com
 
Neural Stem Cells and Therapy 
 
332 
Englund, U., Bjorklund, A., Wictorin, K., Lindvall, O., Kokaia, M. (2002) Grafted neural stem 
cells develop into functional pyramidal neurons and integrate into host cortical 
circuitry. Proc Natl Acad Sci USA, 99:17089–17094. 
Eriksson, P.S., Perfilieva, E., Bjork-Eriksson, T., Alborn, A.M., Nordborg, C., Peterson, D.A., 
Gage, F.H. (1998) Neurogenesis in the adult human hippocampus. Nat Med., 
4:1313–1317. 
Fallon, J., Reid, S., Kinyamu, R., Opole, I.., Opole, R., Baratta, J., Korc, M., Endo, T.L., Duong, 
A., Nguyen, G., Karkehabadhi, M., Twardzik, D., Patel, S., Loughlin, S. (2000) In 
vivo induction of massive proliferation, directed migration, and differentiation of 
neural cells in the adult mammalian brain. Proc Natl Acad Sci USA, 97:14686-91. 
Foulkes, M.A., Wolf, P.A., Price, T.R., Mohr, J.P., Hier, D.B. (1988) The Stroke Data Bank: 
design, methods, and baseline characteristics. Stroke, 19:547-54. 
Francis, F., Koulakoff, A., Boucher, D., Chafey, P., Schaar, B., Vinet, M.C., Friocourt, G., 
McDonnell, N., Reiner, O., Kahn, A., McConnell, S.K., Berwald-Netter, Y., 
Denoulet, P., Chelly, J. (1999) Doublecortin is a developmentally regulated, 
microtubule-associated protein expressed in migrating and differentiating neurons. 
Neuron, 23:247-56. 
Frey, W.H. 2nd, Liu, J., Chen, X., Thorne, R.G., Fawcett, J.R., Ala, T.A., Rahman, Y.E. (1997) 
Delivery of 125I-NGF to the brain via the olfactory route. Drug Delivery, 4:87-92. 
Frinchi, M., Di Liberto, V., Olivieri, M., Fuxe, K., Belluardo, N., Mudò, G. (2010) FGF-
2/FGFR1 neurotrophic system expressionlevel and its basal activation do not 
account for the age-dependent decline of precursor cell proliferation in the 
subventricular zone of rat brain. Brain Res., 1358:39–45. 
Fuchs, E., Tumbar, T., Guasch, G. (2004) Socializing with the neighbors: stem cells and their 
niche. Cell, 116:769–778. 
Fujiwara, Y., Tanaka, N., Ishida, O., Fujimoto, Y., Murakami, T., Kajihara, H., Yasunaga, Y., 
Ochi, M. (2004) Intravenously injected neural progenitor cells of transgenic rats can 
migrate to the injured spinal cord and differentiate into neurons, astrocytes and 
oligodendrocytes. Neurosci Lett., 366:287–291.  
Galvão, R.P., Garcia-Verdugo, J.M., Alvarez-Buylla, A. (2008) Brain-derived neurotrophic 
factor signaling does not stimulate subventricular zone neurogenesis in adult mice 
and rats. J Neurosci., 28: 13368-13383. 
García-Verdugo, J.M., Doetsch, F., Wichterle, H., Lim, D.A., Alvarez-Buylla, A. (1998) 
Architecture and cell types of the adult subventricular zone: in search of the stem 
cells. J Neurobiol., 36:234-248. 
Gascon, E., Vutskits, L., Jenny, B., Durbec, P., Kiss, J.Z.  (2007)  PSA-NCAM in postnatally 
generated immature neurons of the olfactory bulb: a crucial role  in  regulating  p75  
expression  and  cell  survival.  Development, 134:1181–1190. 
Ghashghaei, H.T., Weber, J., Pevny, L., Schmid, R., Schwab, M.H., Lloyd, K.C.K., Eisenstat, 
D.D., Lai, C., Anton, E.S. (2006) The role of neuregulin–ErbB4 interactions on the 
proliferation and organization of cells in the subventricular zone. Proc Natl Acad Sci 
USA, 103:1930–1935. 
Giger, R.J., Pasterkamp, R.J., Heijnen, S., Holtmaat, A.J., Verhaagen, J. (1998) Anatomical 
distribution of the chemorepellent semaphorin III/collapsin-1 in the adult rat and 
human brain: predominant expression in structures of the olfactory-hippocampal 
pathway and the motor system. J Neurosci Res., 52:27–42. 
www.intechopen.com
 
Neural Stem Cells: Exogenous and Endogenous Promising Therapies for Stroke 
 
333 
Giger, R.J., Cloutier, J.F., Sahay, A., Prinjha, R.K., Levengood, D.V., Moore, S.E., Pickering, 
S., Simmons, D., Rastan, S., Walsh, F.S., Kolodkin, A.L., Ginty, D.D., Geppert, M. 
(2000) Neuropilin-2 is required in vivo for selective axon guidance responses to 
secreted semaphorins. Neuron, 25:29–41. 
Giuliani, A., D’Intino, G., Paradisi, M., Giardino, L., Calza, L.  (2004) p75(NTR)- 
immunoreactivity in the subventricular zone of adult male rats: expression by 
cycling cells. J Mol Histol., 35:749–758 
Gleason, D., Fallon, J.H., Guerra, M., Liu, J.C., Bryant, P.J. (2008) Ependymal stem cells 
divide asymmetrically and transfer progeny into the subventricular zone when 
activated by injury. Neuroscience, 156:81-8. 
Gleeson, J.G., Lin, P.T., Flanagan, L.A., Walsh, C.A. (1999) Doublecortin is a microtubule-
associated protein and is expressed widely by migrating neurons. Neuron, 23:257-
71. 
Greenberg, D.A., Jin, K. (2006) Growth factors and stroke. NeuroRx, 3:458-65. 
Gritti, A., Parati, E.A., Cova, L., Frolichsthal, P., Galli, R., Wanke, E., Faravelli, L., 
Morassutti, D.J., Roisen, F., Nickel, D.D., Vescovi, A.L. (1996) Multipotential stem 
cells from the adult mouse brain proliferate and self-renew in response to basic 
fibroblast growth factor. J Neurosci., 16:1091–1100. 
Gritti, A., Frölichsthal-Schoeller, P., Galli, R., Parati, E.A., Cova, L., Pagano, S.F., Bjornson, 
C.R., Vescovi, A.L. (1999)  Epidermal and fibroblast growth factors behave as 
mitogenic regulators for a single multipotent stem cell-like population from the 
subventricular region of the adult mouseforebrain. J Neurosci., 19:3287-3297. 
Gritti, A., Bonfanti, L., Doetsch, F., Caille, I., Alvarez-Buylla, A., Lim D., Galli R., Garcia-
Verdugo J.M., Herrera, D.G., Vescovi, A.L. (2002) multipotent neural stem cells 
reside into the rostral extension and olfactory bulb of adult rodents. J Neurosci., 
22:437-445. 
Guerra-Crespo, M., Gleason, D., Sistos, A., Toosky, T., Solaroglu, I., Zhang, J.H., Bryant, P.J., 
Fallon, J.H. (2009) Transforming growth factor-alpha induces neurogenesis and 
behavioral improvement in a chronic stroke model. Neuroscience, 160:470-83.  
Guerra-Crespo, M., Sistos, A., Gleason, D., Fallon, J.H. (2010) Intranasal administration of 
PEGylated transforming growth factor-alpha improves behavioral deficits in a 
chronic stroke model. J Stroke Cerebrovasc Dis., 19:3-9. 
Gustafsson, E., Andsberg, G., Darsalia, V., Mohapel, P., Mandel, R.J., Kirik, D., Lindvall, O., 
Kokaia, Z. (2003) Anterograde delivery of brain-derived neurotrophic factor to 
striatum via nigral transduction of recombinant adeno-associated virus increases 
neuronal death but promotes neurogenic response following stroke. Eur J Neurosci, 
17:2667-2678. 
Hack, I., Bancila, M., Loulier, K., Carroll, P., Cremer, H. (2002) Reelin is a detachment signal 
in tangential chain-migration during postnatal neurogenesis. Nat Neurosci., 5: 939–
945. 
Hacke, W., Donnan, G., Fieschi, C., Kaste, M., von Kummer, R., Broderick, J.P., Brott T, 
Frankel M, Grotta JC, Haley EC Jr, Kwiatkowski T, Levine SR, Lewandowski C, Lu 
M, Lyden P, Marler JR, Patel S, Tilley BC, Albers G, Bluhmski E, Wilhelm M, 
Hamilton S, ATLANTIS Trials Investigators, ECASS Trials Investigators, NINDS rt-
PA Study Group Investigators. (2004) Association of outcome with early stroke 
www.intechopen.com
 
Neural Stem Cells and Therapy 
 
334 
treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. 
Lancet, 363:768–774. 
Herrera, D.G., Garcia-Verdugo, J.M., Alvarez-Buylla, A. (1999) Adult-derived neural 
precursors transplanted into multiple regions in the adult brain. Ann Neurol., 
46:867–877. 
Hicks, A.U., Lappalainen, R.S., Narkilahti, S., Suuronen, R., Corbett, D., Sivenius, J., 
Hovatta, O., Jolkkonen, J. (2009) Transplantation of human embryonic stem cell-
derived neural precursor cells and enriched environment after cortical stroke in 
rats: cell survival and functional recovery. Eur J Neurosci., 29:562-574.  
Hiesberger, T., Trommsdorff, M., Howell, B.W., Goffinet, A., Mumby, M.C., Cooper, J.A., 
Herz, J. (1999) Direct binding of Reelin to VLDL receptor ApoE receptor 2 induces 
tyrosine phosphorylation of disabled-1 and modulates tau phosphorylation. 
Neuron, 24:481--489. 
Höglinger, G.U., Rizk, P., Muriel, M.P., Duyckaerts, C., Oertel, W.H., Caille, I., Hirsch, E.C. 
(2004) Dopamine depletion impairs precursor cell proliferation in Parkinson 
disease. Nat Neurosci., 7:726-7235. 
Holmberg, J., Armulik, A., Senti, K.A., Edoff, K., Spalding, K., Momma, S., Cassidy, R., 
Flanagan, J.G., Frisén, J. (2005) Ephrin-A2 reverse signaling negatively regulates 
neural progenitor proliferation and neurogenesis Genes Dev., 19:462-471. 
Hu, H., Tomasiewicz, H., Magnuson, T., Rutishauser, U. (1996) The role of polysialic acid in 
migration of olfactory bulb interneuron precursors in the subventricular zone. 
Neuron, 16:735–743. 
Hu, H.  (1999) Chemorepulsion of neuronal migration by Slit2 in the developing mammalian 
forebrain. Neuron, 23:703–711.  
Hu, H. (2000) Polysialic acid regulates chain formation by migrating olfactory interneuron 
precursors. J Neurosci Res., 61:480–492. 
Hynes, R.O. (2002) Integrins: Bidirectional, Allosteric Signaling Machines. Cell, 110:673–687. 
Ishibashi, S., Sakaguchi, M., Kuroiwa, T., Yamasaki, M., Kanemura, Y., Shizuko, I., 
Shimazaki, T., Onodera, M., Okano, H., Mizusawa, H. (2004) Human neural 
stem/progenitor cells, expanded in long-term neurosphere culture, promote 
functional recovery after focal ischemia in Mongolian gerbils. J Neurosci Res., 
78:215-223. 
Itoh, N., Ornitz, D.M. (2011) Fibroblast growth factors: from molecular evolution to roles in 
development, metabolism and disease. J Biochem., 149:121–130. 
Jacques, T.S., Relvas, J.B., Nishimura, S., Pytela, R., Edwards, G.M., Streuli, C.H., ffrench-
Constant, C. (1998) Neural precursor cell chain migration and division are 
regulated through different beta1 integrins. Development, 125:3167-3177. 
Jiang, Q., Zhang, Z.G., Ding, G.L., Silver, B., Zhang, L., Meng, H., Lu, M., Pourabdillah-
Nejed-D, S., Wang, L., Savant-Bhonsale, S., Li, L., Bagher-Ebadian, H., Hu, J., 
Arbab, A.S., Vanguri, P., Ewing, J.R., Ledbetter, K.A., Chopp, M. (2006) MRI detects 
white matter reorganization after neural progenitor cell treatment of stroke. 
Neuroimage, 32:1080-1089.  
Jin, K., Minami, M., Lan, J.Q., Mao, X.O., Batteur, S., Simon, R.P., Greenberg, D.A. (2001) 
Neurogenesis in dentate subgranular zone and rostral subventricular zone after 
focal cerebral ischemia in the rat. Proc Natl Acad Sci USA, 98:4710-5. 
www.intechopen.com
 
Neural Stem Cells: Exogenous and Endogenous Promising Therapies for Stroke 
 
335 
Jin, K., Zhu, Y., Sun, Y., Mao, X.O., Xie, L., Greenberg, D.A.  (2002) Vascular endothelial 
growth factor (VEGF) stimulates neurogenesis in vitro and in vivo. Proc Natl Acad 
Sci USA, 99:11946–11950. 
Jin, K., Sun, Y., Xie, L., Batteur, S., Mao, X.O., Smelick, C., Logvinova, A., Greenberg, D.A. 
(2003) Neurogenesis and aging: FGF-2 and HB-EGF restore neurogenesis in 
hippocampus and subventricular zone of aged mice. Aging Cell, 2:175-183. 
Jin, K., Sun, Y., Xie, L., Childs, J., Mao, X.O., Greenberg, D.A. (2004) Post-ischemic 
administration of heparin-binding epidermal growth factor-like growth factor (HB-
EGF) reduces infarct size and modifies neurogenesis after focal cerebral ischemia in 
the rat. J Cereb Blood Flow Metab., 24:399-408. 
Jin, K., Wang, X., Xie, L., Mao, X.O., Zhu, W., Wang, Y., Shen, J., Mao, Y., Banwait, S., 
Greenberg, D.A. (2006) Evidence for stroke-induced neurogenesis in the human 
brain. Proc Natl Acad Sci USA, 103:13198-202. 
Jin, K., Mao, X., Xie, L., Galvan, V., Lai, B., Wang, Y., Gorostiza, O., Wang, X., Greenberg, 
D.A. (2010a) Transplantation of human neural precursor cells in Matrigel 
scaffolding improves outcome from focal cerebral ischemia after delayed 
postischemic treatment in rats. J. Cereb. Blood Flow Metab., 30:534–544. 
Jin, K., Mao, X., Xie, L., Greenberg, R.B., Peng, B., Moore, A., Greenberg, M.B., Greenberg, 
D.A. (2010b) Delayed transplantation of human neural precursor cells improves 
outcome from focal cerebral ischemia in aged rats. Aging Cell, 9:1076–108. 
Johansson, C.B., Momma, S., Clarke, D.L., Risling, M., Lendahl, U., Frisén, J. (1999) 
Identification of a neural stem cell in the adult mammalian central nervous system. 
Cell, 96: 25–34.  
Johnson, D.E., Williams, L.T. (1993) Structural and functional diversity in the FGF receptor 
multigene family. Adv. Cancer Res., 60:1–41. 
Kawai, H., Yamashita, T., Ohta, Y., Deguchi, K., Nagotani, S., Zhang, X., Ikeda, Y., Matsuura, 
T., Abe, K. (2010) Tridermal tumorigenesis of induced pluripotent stem cells 
transplanted in ischemic brain. J Cereb Blood Flow Metab., 30:1487-1493. 
Kelly, S., Bliss, T.M., Shah, A.K., Sun, G.H., Ma, M., Foo, W.C., Masel, J., Yenari, M.A., 
Weissman, I.L., Uchida, N., Palmer, T., Steinberg, G.K. (2004) Transplanted human 
fetal neural stem cells survive, migrate, and differentiate in ischemic rat cerebral 
cortex. Proc Natl Acad Sci., U S A, 101:11839–11844. 
Koizumi, H., Higginbotham, H., Poon, T., Tanaka, T., Brinkman, B.C., Gleeson, J.G. (2006) 
Doublecortin maintains bipolar shape and nuclear translocation during migration 
in the adult forebrain. Nat Neurosci., 9:779–786. 
Komitova, M., Zhu, X., Serwanski, D.R., Nishiyama, A. (2009) NG2 cells are distinct from 
neurogenic cells in the postnatal mouse subventricular zone. J Comp Neurol., 
512:702-16. 
Kondziolka, D., Steinberg, G.K., Wechsler, L., Meltzer, C.C., Elder, E., Gebel, J., Decesare, S., 
Jovin, T., Zafonte, R., Lebowitz, J., Flickinger, J.C., Tong, D., Marks, M.P., Jamieson, 
C., Luu, D., Bell-Stephens, T., Teraoka, J. (2005) Neurotransplantation for patients 
with subcortical motor stroke: a phase 2 randomized trial. J Neurosurg., 103:38-45. 
Kuhn, H.G., Winkler, J., Kempermann, G., Thal, L.J., Gage, F.H.  (1997)  Epidermal  growth  
factor  and fibroblast  growth  factor-2  have  differenteffects  on  neural  
progenitors  in  the  adult  rat  brain.  J  Neurosci., 17:5820-5828. 
www.intechopen.com
 
Neural Stem Cells and Therapy 
 
336 
Lee, J.P., Jeyakumar, M., Gonzalez, R., Takahashi, H., Lee, P.J., Baek, R.C., Clark, D., Rose, 
H., Fu, G., Clarke, J., McKercher, S., Meerloo, J., Muller, F.J., Park, K.I., Butters, T.D., 
Dwek, R.A., Schwartz, P., Tong, G., Wenger, D., Lipton, S.A., Seyfriend, T.N., Platt, 
F.M., Snyder, E.Y. (2007) Stem cells act through multiple mechanisms to benefit 
mice with neurodegenerative metabolic disease. Nat Med., 13:439–447. 
Leker, R.R., Soldner, F., Velasco, I., Gavin, D.K., Androutsellis-Theotokis, A., McKay, R.D. 
(2007) Long-lasting regeneration after ischemia in the cerebral cortex. Stroke, 38:153-
161. 
Leker, R.R., Toth, Z.E., Shahar, T., Cassiani-Ingoni, R., Szalayova, I., Key, S., Bratincsák, A., 
Mezey, E. (2009) Transforming growth factor alpha induces angiogenesis and 
neurogenesis following stroke. Neuroscience, 163:233-43. 
Li, H.S., Chen, J.H., Wu, W., Fagaly, T., Zhou, L., Yuan, W., Dupuis, S., Jiang, Z.H., Nash, 
W., Gick, C. (1999) Vertebrate slit, a secreted ligand for the transmembrane protein 
roundabout, is a repellent for olfactory bulb axons. Cell, 96:807-818. 
Liu, J., Solway, K., Messing, R.O., Sharp, F.R. (1998) Increased neurogenesis in the dentate 
gyrus after transient global ischemia in gerbils. J Neurosci., 18:7768-78. 
Liu, X.F., Fawcett, J.R., Hanson, L.R., Frey, W.H. 2nd. (2004) The window of opportunity for 
treatment of focal cerebral ischemic damage with noninvasive intranasal insulin-
like growth factor-I in rats. J Stroke Cerebrovasc Dis., 13:16-23. 
Lledo, P.M., Merkle, F.T.,  Alvarez-Buylla, A. (2008) Origin and function of olfactory bulb 
interneuron diversity. Trends Neurosci., 31:392-400. 
Lois, C., Alvarez-Buylla, A. (1994), Long distance neuronal migration in the adult 
mammalian brain. Science, 264:1145–1148. 
Lois, C., Garcia-Verdugo, J.M., Alvarez-Buylla, A. (1996) Chain migration of neuronal 
precursors. Science, 271:978–981.  
Ma, M., Ma, Y., Yi, X., Guo, R., Zhu, W., Fan, X., Xu, G., Frey, W.H. 2nd, Liu, X. (2008) 
Intranasal delivery of transforming growth factor-beta1 in mice after stroke reduces 
infarct volume and increases neurogenesis in the subventricular zone. BMC 
Neurosci., 9:117. 
Maisonpierre, P.C., Belluscio, L., Friedman, B., Alderson, R.F., Wiegand, S.J., Furth, M.E., 
Lindsay, R.M., Yancopoulos, G.D. (1990) NT-3, BDNF, and NGF in the developing 
rat nervous system: parallel as well as reciprocal patterns of expression. Neuron, 
5:501-509. 
Marillat, V., Cases, O., Nguyen-Ba-Charvet, K.T., Tessier-Lavigne, M., Sotelo, C., Chedotal, 
A. (2002) Spatiotemporal expression patterns of slit and robo genes in the rat brain. 
J Comp Neurol., 442:130–155. 
Martí-Fàbregas, J., Romaguera-Ros, M., Gómez-Pinedo, U., Martínez-Ramírez, S., Jiménez-
Xarrié, E., Marín, R., Martí-Vilalta, J.L., García-Verdugo, J.M. (2010) Proliferation in 
the human ipsilateral subventricular zone after ischemic stroke. Neurology, 74:357-
65. 
Martino,. G, Pluchino, S. (2006) The therapeutic potential of neural stem cells. Nat Rev 
Neurosci., 7:395–406. 
Matsumoto, T., Claesson-Welsh, L. (2001) VEGF receptor signal transduction. Sci. STKE, 
2001:Re21.  
www.intechopen.com
 
Neural Stem Cells: Exogenous and Endogenous Promising Therapies for Stroke 
 
337 
Matsuoka, N., Nozaki, K., Takagi, Y., Nishimura, M., Hayashi, J., Miyatake, S., Hashimoto, 
N. (2003) Adenovirus-mediated gene transfer of fibroblast growth factor-2 
increases BrdU-positive cells after forebrain ischemia in gerbils. Stroke, 34:1519-25. 
Mattsson, B., Sorensen, J.C., Zimmer, J., Johansson, B.B. (1997) Neural grafting to 
experimental neocortical infarcts improves behavioral outcome and reduces 
thalamic atrophy in rats housed in enriched but not in standard environments. 
Stroke, 28:1225–1231.  
Meléndez-Herrera, E., Colín-Castelán, D., Varela-Echavarría, A., Gutiérrez-Ospina, G. (2008) 
Semaphorin-3A and its receptor neuropilin-1 are predominantly expressed in 
endothelial cells along the rostral migratory stream of young and adult mice. Cell 
Tissue Res., 333:175-84. 
Mirzadeh, Z., Merkle, F. T., Soriano-Navarro, M., Garcia-Verdugo, J. M., Alvarez-Buylla, A. 
(2008) Neural stem cells confer unique pinwheel architecture to the ventricular 
surface in neurogenic regions of the adult brain. Cell Stem Cell, 3:265–278. 
Modo, M., Stroemer, R.P., Tang, E., Patel, S., Hodges, H. (2002) Effects of implantation site of 
stem cell grafts on behavioral recovery from stroke damage. Stroke, 33:2270–2278. 
Moores, C.A., Perderiset, M., Francis, F., Chelly, J., Houdusse, A., Milligan, R.A. (2004) 
Mechanism of microtubule stabilization by doublecortin. Mol Cell, 14:833-9. 
Morshead, C.M., Garcia, A.D., Sofroniew, M.V., van Der Kooy, D. (2003) The ablation of 
glial fibrillary acidic proteinpositive cells from the adult central nervous system 
results in the loss of forebrain neural stem cells but not retinal stem cells. Eur J 
Neurosci., 18:76–84. 
Mosch, B., Reissenweber, B., Neuber, C., Pietzsch, J. (2010) Eph receptors and ephrin 
ligands: Important players in angiogenesis and tumor angiogenesis. J Onc., 2010:1-
12. 
Mudó, G., Belluardo, N., Fuxe, K. (2007) Acute intermittent nicotine treatment induces 
fibroblast growth factor-2 in the subventricular zone of the adult rat brain and 
enhances neuronal precursor cell proliferation. Neuroscience, 145:470-83. 
Murase, S., Horwitz, A. F. (2002) deleted in colorectal carcinoma and differentially expressed 
integrins mediate the directional migration of neural precursors in the rostral 
migratory stream. J Neurosci., 22:3568–3579. 
Murase, S., Cho, C., White, J.M., Horwitz, A.F. (2008) ADAM2 promotes migration of 
neuroblasts in the rostral migratory stream to the olfactory bulb. Eur J Neurosci., 
27:1585-95. 
Nakatomi, H., Kuriu, T., Okabe, S., Yamamoto, S., Hatano, O., Kawahara, N., Tamura, A., 
Kirino, T., Nakafuku, M. (2002) Regeneration of hippocampal pyramidal neurons 
after ischemic brain injury by recruitment of endogenous neural progenitors. Cell, 
110:429-41. 
Ng, K.L., Li, J.D., Cheng, M.Y., Leslie, F.M., Lee, A.G., Zhou, Q.Y. (2005) Dependence of 
olfactory bulb neurogenesis on prokineticin 2 signaling. Science, 308:1923–1927. 
Nguyen-Ba-Charvet, K.T., Picard-Riera, N., Tessier-Lavigne, M., Baron-Van, Evercooren, A., 
Sotelo, C., Chedotal, A. (2004) Multiple roles for slits in the control of cell migration 
in the rostral migratory stream.  J Neurosci., 24:1497–1506. 
Nishino, H., Borlongan, C.V. (2000) Restoration of function by neural transplantation in the 
ischemic brain. Prog. Brain Res., 127:461–476. 
www.intechopen.com
 
Neural Stem Cells and Therapy 
 
338 
Ocbina, P.J., Dizon, M.L., Shin, L., Szele, F.G. (2006) Doublecortin is necessary for the 
migration of adult subventricular zone cells from neurospheres. Mol Cell Neurosci., 
33:126-35.  
Ornitz, D.M., Xu, J., Colvin, J.S., McEwen, D.G., MacArthur, C.A., Coulier, F., Gao, G., 
Goldfarb, M. (1996) Receptor specificity of the fibroblast growth factor family. J Biol 
Chem., 271:15292–15297. 
Ourednik, J., Ourednik, V., Lynch, W.P., Schachner, M., Snyder, E.Y. (2002) Neural stem 
cells display an inherent mechanism for rescuing dysfunctional neurons. Nat 
Biotechnol., 20:1103–1110.  
Parent, J.M., Vexler, Z.S., Gong, C., Derugin, N., Ferriero, D.M. (2002) Rat forebrain 
neurogenesis and striatal neuron replacement after focal stroke. Ann Neurol., 
52:802-13. 
Park, K.I., Lachyankar, M., Nissim, S., Snyder, E.Y. (2002) Neural stem cells for CNS repair: 
state of the art and future directions. Adv Exp Med Biol., 506:1291-1296. 
Pencea, V., Bingaman, K.D., Wiegand, S.J., Luskin, M.B.  (2001)  Infusion of brain-derived 
neurotrophic factor into the lateral ventricle of the adult rat leads to new neurons in 
the parenchyma of the striatum, septum, thalamus, and hypothalamus. J Neurosci., 
21:6706–6717. 
Petridis, A.K., El-Maarouf, A., Rutishauser, U. (2004) Polysialic acid regulates cell contact-
dependent neuronal differentiation of progenitor cells from the subventricular 
zone. Dev Dyn., 230:675–684. 
Pluchino, S., Quattrini, A., Brambilla, E., Gritti, A., Salani, G., Dina, G., Galli, R., Del Carro, 
U., Amadio, S., Bergami, A., Furlan, R., Comi, G., Vescovi, A.L., Martino, G. (2003) 
Injection of adult neurospheres induces recovery in a chronic model of multiple 
sclerosis. Nature, 422:688–694. 
Pollock, K., Stroemer, P., Patel, S., Stevanato, L., Hope, A., Miljan, E., Dong, Z., Hodges, H., 
Price, J., Sinden, J.D. (2006) A conditional immortal clonal stem line from human 
cortical neuroepithelium for the treatment of ischemic stroke. Exp Neurol., 199:143–
155. 
Prosser, H.M., Bradley, A., Caldwell, M.A. (2007) Olfactory bulb hypoplasia in Prokr2 null 
mice stems from defective neuronal progenitor migration and differentiation. Eur J 
Neurosci., 12: 3339–3344. 
Raper, J.A. (2000) Semaphorins and their receptors in vertebrates and invertebrates. Curr Op  
Neurobiol., 10:88–94. 
Reuss, B., Von, Bohlen., Halbach, O. (2003) Fibroblast growth factors and their receptors in 
the central nervous system. Cell Tissue Res., 313:139–157 
Reynolds, B.A., Weiss, S. (1992) Generation of neurons and astrocytes from isolated cells of 
the adult mammalian central nervous system. Science, 255:1707-1710. 
Reynolds, B.A., Weiss, S. (1996) Clonal and population analyses demonstrate that an EGF-
responsive mammalian embryonic CNS precursor is a stem cell. Dev Biol., 175:1–13. 
Riolobos, A. S., Heredia, M., de la Fuente, J.A., Criado, J.M., Yajeya, J., Campos, J., 
Santacana, M. (2001) Functional recovery of skilled forelimb use in rats obliged to 
use the impaired limb after grafting of the frontal cortex lesion with homotopic 
fetal cortex. Neurobiol Learn Mem., 75:274–292. 
Ropper, A.H., Brown, R.H. (2009) Adams and Victor’s principles of neurology, 9th Ed. New 
York: McGraw-Hill. 
www.intechopen.com
 
Neural Stem Cells: Exogenous and Endogenous Promising Therapies for Stroke 
 
339 
Rousselot, P., Lois, C., Alvarez-Buylla, A. (1995) Embryonic (PSA) N-CAM reveals chains of 
migrating neuroblasts between the lateral ventricle and the olfactory bulb of adult 
mice. J Comp Neurol., 351:51-61. 
Saghatelyan, A., de Chevigny, A., Schachner, M., Lledo, P.M. (2004). Tenascin-R mediates 
activity-dependent recruitment of neuroblasts in the adult mouse forebrain. Nat 
Neurosci., 7:347–356.  
Saporta, S., Borlongan, C.V., Sanberg, P.R. (1999) Neural transplantation of human 
neuroteratocarcinoma (hNT) neurons into ischemic rats. A quantitative dose-
response analysis of cell survival and behavioral recovery. Neuroscience, 91:519–525. 
Savitz, S.I., Rosenbaum, D.M., Dinsmore, J.H., Weschler, L.R., Caplan, L.R. (2002) Cell 
transplantation for stroke Ann. Neurol., 53:266–275. 
Savitz, S.I., Dinsmore, J., Wu, J., Henderson, G.V., Stieg, P., Caplan, L.R. (2005) 
Neurotransplantation of fetal porcine cells in patients with basal ganglia infarcts: a 
preliminary safety and feasibility study. Cerebrovasc Dis., 20:101-107. 
Schabitz, W.R., Steigleder, T., Cooper-Kuhn, C.M., Schwab, S., Sommer, C., Schneider, A., 
Kuhn, H.G. (2007) Intravenous brain-derived neurotrophic factor enhances 
poststroke sensorimotor recovery and stimulates neurogenesis. Stroke, 38:2165–
2172. 
Schänzer, A., Wachs, F.P., Wilhelm, D., Acker, T., Cooper-Kuhn, C., Beck, H., Winkler, J., 
Aigner, L., Plate, KH., Kuhn, H.G. (2004) Direct stimulation of adult neural stem 
cells in vitro and neurogenesis in vivo by vascular endothelial growth factor. Brain 
Pathol., 14:237-48. 
Scheffler, B., Walton, N.M., Lin, D.D., Goetz, A.K., Enikolopov, G., Roper, S.N., Steindler, 
D.A. (2005) Phenotypic and functional characterization of adult brain neuropoiesis. 
Proc Natl Acad Sci., U S A, 102:9355–9358. 
Seki, T., Arai, Y. (1993) Highly polysialylated neural cell adhesion molecule (NCAM-H) is 
expressed by newly generated granule cells in the dentate gyrus of the adult rat. J 
Neurosci., 13:2351–2358. 
Shen, Q., Wang, Y., Kokovay, E., Lin, G., Chuang, S.M., Goderie, S.K., Roysam, B., Temple, 
S. (2008) Adult SVZ stem cells lie in a vascular niche: a quantitative analysis of 
niche cell-cell interactions. Cell Stem Cell, 3:289–300. 
Sinden, J.D., Rashid-Doubell, F., Kershaw, T.R., Nelson, A., Chadwick, A., Jat, P.S., Noble, 
M.D., Hodges, H., Gray, J.A. (1997) Recovery of spatial learning by grafts of a 
conditionally immortalized hippocampal neuroepithelial cell line into the 
ischaemia-lesioned hippocampus. Neuroscience, 81:599–608. 
Snapyan, M., Lemasson, M., Brill, M.S., Blais, M., Massouh, M., Ninkovic, J., Gravel, C., 
Berthod, F., Götz, M., Barker, P.A., Parent, A.,Saghatelyan, A. (2009) Vasculature 
guides migrating neuronal precursors in the adult mammalian forebrain via brain-
derived neurotrophic factor signaling. J Neurosci., 29:4172-4188. 
Soker,  S., Takashima, S., Miao, H.Q., Neufeld, G., Klagsbrun, M. (1998) Neuropilin-1 is 
expressed by endothelial and tumor cells as an isoformspecific receptor for vascular 
endothelial growth factor. Cell, 92:735-745. 
Song, H.J., Stevens, C.F., Gage, F.H. (2002a) Astroglia induce neurogenesis from adult neural 
stem cells. Nature, 417:39–44. 
Song, H.J., Stevens, C.F., Gage, F.H. (2002b) Neural stem cells from adult hippocampus 
develop essential properties of functional CNS neurons. Nat Neurosci., 5:438–445. 
www.intechopen.com
 
Neural Stem Cells and Therapy 
 
340 
Stilley, C.S., Ryan, C.M., Kondziolka, D., Bender, A., DeCesare, S., Wechsler, L. (2004) 
Changes in cognitive function after neuronal cell transplantation for basal ganglia 
stroke. Neurology, 63:1320-1322.  
Suárez-Monteagudo, C., Hernández-Ramírez, P., Alvarez-González, L., García-Maeso, I., de 
la Cuétara-Bernal, K., Castillo-Díaz, L., Bringas-Vega, M.L., Martínez-Aching, G., 
Morales-Chacón, L.M., Báez-Martín, M.M., Sánchez-Catasús, C., Carballo-Barreda, 
M., Rodríguez-Rojas, R., Gómez-Fernández, L., Alberti-Amador, E., Macías-
Abraham, C., Balea, E.D., Rosales, L.C., Del Valle Pérez, L., Ferrer, B.B., González, 
R.M., Bergado, J.A. (2009) Autologous bone marrow stem cell neurotransplantation 
in stroke patients. An open study. Restor Neurol Neurosci., 27:151-161. 
Sugiura, S., Kitagawa, K., Tanaka, S., Todo, K., Omura-Matsuoka, E., Sasaki, T., Mabuchi, T., 
Matsushita, K., Yagita, Y., Hori, M. (2005) Adenovirus-mediated gene transfer of 
heparin-binding epidermal growth factor-like growth factor enhances neurogenesis 
and angiogenesis after focal cerebral ischemia in rats. Stroke, 36:859-864. 
Sun, Y., Jin, K., Childs, J.T., Xie, L., Mao, X.O., Greenberg, D.A. (2006) Vascular endothelial 
growth factor-B (VEGFB) stimulates neurogenesis: Evidence from knockout mice 
and growth factor administration. Dev Biol., 289:329–33. 
Tamagnone, L., Comoglio, P.M. (2000) Signaling by semaphorin receptors: cell guidance and 
beyond. Trends Cell Biol., 10, 377–383. 
Teramoto, T., Qiu, J., Plumier, J.C., Moskowitz, M.A. (2003) EGF amplifies the replacement 
of parvalbumin-expressing striatal interneurons after ischemia. J Clin Invest., 
111:1125-1132. 
Theus, M.G., Ricard, J., Bethea, J.R., Liebl, D.J. (2010) EphB3 limits the expansion of neural 
progenitor cells in the subventricular zone by regulatinf p53 during homeostasis 
and following traumatic brain injury. Stem Cells, 28:1231-1242. 
Thored, P., Arvidsson, A., Cacci, E., Ahlenius, H., Kallur, T., Darsalia, V., Ekdahl, C.T., 
Kokaia, Z., Lindvall, O. (2006) Persistent production of neurons from adult brain 
stem cells during recovery after stroke. Stem Cells, 24:739-47. 
Thorne, R.G., Pronk, G.J., Padmanabhan, V., Frey, W.H. 2nd. (2004) Delivery of insulin-like 
growth factor-I to the rat brain and spinal cord along olfactory and trigeminal 
pathways following intranasal administration. Neuroscience, 127:481-96. 
Tropepe, V., Craig, C.G., Morshead, C.M., van der Kooy, D. (1997) Transforming growth 
factor-alpha null and senescent mice show decreased neural progenitor cell 
proliferation in the forebrain subependyma. J Neurosci., 17:7850–7859. 
Vahedi, K., Hofmeijer, J., Juettler, E., Vicaut, E., George, B., Algra, A., Amelink, G.J., 
Schmiedeck, P., Schwab,   S., Rothwell, P.M., Bousser, M.G., van der Worp, H.B., 
Hacke, W., DECIMAL, DESTINY, and HAMLET investigators. (2007) Early 
decompressive surgery in malignant infarction of the middle cerebral artery: a 
pooled analysis of three randomised controlled trials. Lancet Neuro., 6:215–222.  
Veizovic, T., Beech, J.S., Stroemer, R.P., Watson, W.P., Hodges, H. (2001) Resolution of 
stroke deficits following contralateral grafts of conditionally immortal 
neuroepithelial stem cells. Stroke, 32:1012–1019. 
Viapiano, M.S., Matthews, R.T. (2006) From barriers to bridges: chondroitin sulfate 
proteoglycans in neuropathology. Trends Mol Med., 12:488-496. 
www.intechopen.com
 
Neural Stem Cells: Exogenous and Endogenous Promising Therapies for Stroke 
 
341 
Wada, K., Sugimori, H., Bhide, P.G., Moskowitz, M.A., Finklestein, S.P. (2003) Effect of basic 
fibroblast growth factor treatment on brain progenitor cells after permanent focal 
ischemia in rats. Stroke, 34:2722-2728. 
Wagner, J.P., Black, I.B., DiCicco-Bloom, E. (1999) Stimulation of neonatal and adult brain 
neurogenesis by subcutaneous injection of basic fibroblast growth factor. J 
Neurosci., 19:6006–6016. 
Wang, Y.Q., Jin, K., Mao, X.O., Xie, L., Banwait, S., Marti, H.H., Greenberg, D.A. (2007a) 
VEGF-overexpressing transgenic mice show enhanced post-ischemic neurogenesis 
and neuromigration. J Neurosci Res., 85:740–747. 
Wang, Y.Q., Guo, X., Qiu, M.H., Feng, X.Y., Sun, F.Y. (2007b) VEGF overexpression 
enhances striatal neurogenesis in brain of adult rat after a transient middle cerebral 
artery occlusion. J Neurosci Res., 85:73–82. 
Wei, L., Cui, L., Snider, B.J., Rivkin, M., Yu, S.S., Lee, C.S., Adams, L.D., Gottlieb, D.I., 
Johnson, E.M. Jr Yu, S.P., Choi, D.W. (2005) Transplantation of embryonic stem 
cells overexpressing Bcl-2 promotes functional recovery after transient cerebral 
ischemia. Neurobiol Dis., 19:183-193. 
Weiss, S., Dunne, C., Hewson, J., Wohl, C., Wheatley, M., Peterson, A.C., Reynolds, B.A. 
(1996) Multipotent CNS stem cells are present in the adult mammalian spinal cord 
and ventricular neuroaxis. J Neurosci., 16:7599–7609. 
Whitman, M.C., Greer, C.A. (2007) Adult-generated neurons exhibit diverse developmental 
fates. Dev. Neurobiol., 67:1079–1093. 
Wilkinson, D.G. (2001) Multiple roles of EPH receptors and ephrins in neural development. 
Multiple roles of EPH receptors and ephrins in neural development. Nat Rev 
Neurosci., 2:155-64. 
Winkler, C., Fricker, R.A., Gates, M.A., Olsson, M., Hammang, J.P., Carpenter, M.K., 
Bjorklund, A. (1998) Incorporation and glial differentiation of mouse EGF-
responsive neural progenitor cells after transplantation into the embryonic rat 
brain. Mol Cell Neurosci., 11:99 –116. 
World Health Organization (2007) World Health Report ; www.who.int. 
Wu, P., Tarasenko, Y.I., Gu, Y., Huang, L.Y., Coggeshall, R.E., Yu, Y. (2002) Region-specific 
generation of cholinergic neurons from fetal human neural stem cells grafted in 
adult rat. Nat Neurosci., 5:1271–1278. 
Wu, W., Wong, K., Chen, J., Jiang, Z., Dupuis, S., Wu, J.Y., Rao, Y. (1999) Directional 
guidance of neuronal migration in the olfactory system by the protein Slit. Nature, 
400:331–336.  
Wurmser, A.E., Nakashima, K., Summers, R.G., Toni, N., D’Amour, K.A., Lie, D.C., Gage, 
F.H. (2004) Cell fusion-independent differentiation of neural stem cells to the 
endothelial lineage. Nature, 430:350 –356. 
Yan, J., Xu, L., Welsh, A.M., Hatfield, G., Hazel, T., Johe, K., Koliatsos, V.E. (2007) Extensive 
neuronal differentiation of human neural stem cell grafts in adult rat spinal cord. 
PLoS Med., 4:e39. 
Yandava, B.D., Billinghurst, L.L., Snyder, E.Y. (1999) “Global” cell replacement is feasible via 
neural stem cell transplantation: evidence from the dysmyelinated shiverer mouse 
brain. Proc Natl Acad Sci U S A, 96:7029–7034. 
www.intechopen.com
 
Neural Stem Cells and Therapy 
 
342 
Yang, P., Baker, K.A., Hagg, T. (2005) A disintegrin and metalloprotease 21 (ADAM21) is 
associated with neurogenesis and axonal growth in developing and adult rodent 
CNS. J Comp Neurol., 490:163–179.  
Yang, P., K., Baker, A., Hagg, T. (2006) The ADAMs family: Coordinators of nervous system 
development, plasticity and repair. Prog Neurobiol., 79:73–94. 
Yarden, Y., Sliwkowski, M.X. (2001) Untangling the ErbB signaling network, Nat Rev Mol 
Cell Biol., 2:127–137. 
Young, K.M., Merson, T.D., Sotthibundhu, A., Coulson, E.J., Bartlett, P.F.  (2007) p75 
neurotrophin receptor expression defines a population of BDNF- responsive 
neurogenic precursor cells. J Neurosci., 27:5146–5155. 
Zhang, H., Vutskits, L., Pepper, M.S., Kiss, J.Z. (2003) VEGF is a chemoattractant for FGF-2-
stimulated neural progenitors J Cell Biol., 163:1375–1384. 
Zhang, P., Li, J., Liu, Y., Chen, X., Kang, Q. (2009a) Transplanted human embryonic neural 
stem cells survive, migrate, differentiate and increase endogenous nestin 
expression in adult rat cortical peri-infarction zone. Neuropathology, 29:410–421. 
Zhang, P., Li, J., Liu, Y., Chen, X., Kang, Q., Zhao, J., Li, W. (2009b) Human neural stem cell 
transplantation attenuates apoptosis and improves neurological functions after 
cerebral ischemia in rats. Acta Anaesthesiol Scand, 53:1184-1191. 
Zhang, P., Li, J., Liu, Y., Chen, X., Lu, H., Kang, Q., Li, W., Gao, M. (2010) Human embryonic 
neural stem cell transplantation increases subventricular zone cell proliferation and 
promotes peri-infarct angiogenesis after focal cerebral ischemia. Neuropathology, 
39:1440-1789. 
Zhang, R.L., Zhang, Z.G., Zhang, L., Chopp, M. (2001) Proliferation and differentiation of 
progenitor cells in the cortex and the subventricular zone in the adult rat after focal 
cerebral ischemia. Neuroscience, 105:33-41. 
Zhao, C., Deng, W., Gage, F.H. (2008) Mechanisms and functional implications of adult 
neurogenesis. Cell, 132:645-60. 
Zhao, L.R., Duan, W.M., Reyes, M., Keene, C.D., Verfaillie, C.M., Low, W.C. (2002) Human 
bone marrow stem cells exhibit neural phenotypes and ameliorate neurological 
deficits after grafting into the ischemic brain of rats Exp. Neurol., 174:11–20. 
Zigova, T., Pencea, V., Wiegand, S.J., Luskin, M.B. (1998) Intraventricular administration of 
BDNF increases the number of newly generated neurons in the adult olfactory 
bulb. Mol Cell Neurosci., 11:234–245. 
www.intechopen.com
Neural Stem Cells and Therapy
Edited by Dr. Tao Sun
ISBN 978-953-307-958-5
Hard cover, 440 pages
Publisher InTech
Published online 15, February, 2012
Published in print edition February, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
This book is a collective work of international experts in the neural stem cell field. The book incorporates the
characterization of embryonic and adult neural stem cells in both invertebrates and vertebrates. It highlights
the history and the most advanced discoveries in neural stem cells, and summarizes the mechanisms of
neural stem cell development. In particular, this book provides strategies and discusses the challenges of
utilizing neural stem cells for therapy of neurological disorders and brain and spinal cord injuries. It is suitable
for general readers, students, doctors and researchers who are interested in understanding the principles of
and new discoveries in neural stem cells and therapy.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
M. Guerra-Crespo, A.K. De la Herrán-Arita, A. Boronat-García, G. Maya-Espinosa, J.R. García-Montes, J.H.
Fallon and R. Drucker-Colín (2012). Neural Stem Cells: Exogenous and Endogenous Promising Therapies for
Stroke, Neural Stem Cells and Therapy, Dr. Tao Sun (Ed.), ISBN: 978-953-307-958-5, InTech, Available from:
http://www.intechopen.com/books/neural-stem-cells-and-therapy/neural-stem-cells-exogenous-and-
endogenous-promising-therapies-for-stroke
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
